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ABBREVIATIONS
DNA Deoxyribonucleic acid
RNA Ribonucleic acid
cdks Cyclin-dependent kinases
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UV Ultraviolet
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T Thymidine
nm Nanometers
dR 2"-Deoxy ribose sugar group
NTs Nucleoside Transporters
DTT Dithiothreitol
S4BrdU 4-Thio-5-bromo-deoxyuridine
S4BrdUDNP S4-2,4-dinitrophenyl-5 -bromodeoxyuridine
CPG controlled porous glass
min v. minutes
s seconds
T™ 4-Triazolothymidine
Tcys 4-Cysteinylthymidine
rpCYs-CYSrp Dimer of 4-cysteinylthymidine
Tglu 4-(S-Glutathionyl)-thymidine
S4-2,4dnpBrdU S4-2,4-dinitrophenyl-5-bromodeoxyuridine 
DNP Dinitrophenyl
ABSTRACT
Cancer is a devastating disease. Numerous drugs have been synthesised over the 
years aiming to cure cancer. Significant new advancements in anti-cancer therapy 
have been achieved over the past few years. This was made possible by the molecular 
level understanding of the cancer disease, which has led to the synthesis of various 
targeted drugs.
The targets within the cancer cells are very limited for anti-cancer drug design 
because cancerous cells resemble normal cells in most of their molecular aspects. 
This makes it extremely difficult for cell specific incorporation of drugs or cell 
killing. So, alternative approaches have been followed for specific cell killing. 
However, such approaches are still at an early stage and a great deal of work needs to 
be done. Various DNA-targeted approaches, such as photo cross-linking and 
chemical cross-linking; have been developed for killing cancerous cells. These 
approaches have not completely solved the problem of specificity. Like traditional 
anti cancer drugs, these agents also indiscriminately cross-link DNA in both normal 
cells, cancerous cells leading to cell death.
In this thesis, two modified nucleosides were chosen which can be incorporated into 
the DNA of the cells easily. These thio-modified nucleosides were proven to have 
more affinity towards the DNA of the cancerous cells. Such modified nucleosides 
have previously been exploited for anti-cancer activity, especially UVA cell killing. 
In this thesis the thio-modified nucleosides have been explored for their site specific 
cross-linking activity.
The first modified nucleoside 4-thiothymidine was synthesised and reported in 1959. 
4-Thiothymidine resembles thymidine, except for a modification at position 4 with 
sulphur instead of oxygen. Previous studies have shown that 4-thiothymidine behaves
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like thymidine when incorporated into the cells. Like thymidine, this is base-paired 
with adenine in DNA. In this thesis, at first the thiol group of 4-thiothymidine has 
been specifically activated by a stable and readily replaceable group. This group was 
then replaced by various thio-nucleophiles which lead to the cross-linking of the 
nucleoside. The standards of these cross-linked nucleosides were successfully 
synthesised and characterised.
In the quest to improve specificity of incorporation into cancer cells a novel pro-drug, 
4-thio-5-bromodeoxyuridine (S4-BrdU) was synthesised by members of our group in 
2003. This nucleoside is another thymidine analogue which is modified by replacing 
oxygen at position 4 with sulphur and methyl at position 5 with bromine. The thiol 
group of S4-BrdU nucleoside was chosen for the purpose of cross-linking.
Successful cross-linking of the nucleoside with various thiol nucleophiles has been 
explored. Firstly S4-BrdU was converted into a DNP derivative. The DNP was then 
replaced with mercaptoethanol, thioethanethiol and natural thiols such as cysteine (the 
only amino acid containing a thiol group in the molecule) and glutathione (a natural 
peptide which helps in detoxification pathways in the body). These cross-linked 
products have been characterised by various methods.
After successfully cross-linking the nucleosides, oligomers containing 4- 
thiothymidine were synthesised. The oligomers were characterised and 4- 
thiothymidine was successfully incorporated into the oligomers.
6
CONTENTS
1 INTRODUCTION
1.1 The Cell 13
1.2 Cell Structure 13
1.3 Organisation of DNA into Chromosome 13
1.4 The Cell Cycle 14
1.5 Chemistry of DNA 15
1.6 DNA damage 18
1.7 Damage to DNA by various agents 19
1.7.1 Chemical Carcinogens 19
1.7.2 Diet 19
1.7.3 Physical Carcinogens 20
1.7.4 DNA damage by free radicals 21
1.8 DNA repair 22
1.9 Cancer Biology 23
1.10 Skin Cancer 24
1.11 Cancer Treatment 24
1.12 Drugs used for Cancer Chemotherapy 25
1.13 Carcinogenic Cancer Chemotherapeutic Agents 28
1.14 Nucleosides and Analogues as Drugs 28
1.15 Sulphur Modified Nucleosides 30
1.16 Thiopurines as Drugs 31 .
1.17 Thiopyrimidines as Drugs 32
1.18 Cross-linking 33
7
1.19 DNA-Protein Cross-linking
1.20 Aims and approaches of the current work
34
35
2. SYNTHESIS AND REACTIONS OF 4-THIOTHYMIDINE
2.1 Synthesis of 4-thiothymidine 38
2.2 Manipulation of 4-thiothymidine 41
2.3 Introduction of DNP on 4-thiothymidine 42
2.4 Stability studies of TSDNP 48
2.4.1 Characterisation of new peaks ; 49
2.5. Reaction of TSDNP with mercaptoethanol 51
2.6 Synthesis of 4-triazolothymidine \ 54
<
2.7 Synthesis of standard 2-hydroxyethylthiothymidine 56
2.7.1 Characteristics of 2-hydroxyethylthiothymidine 59
2.8 Synthesis of 4-ethylthiothymidine 62
2.9 Amino acid cross-linking - t sdnp with Cysteine 64
2.9.1 Reducing disulfide bonds 74
2.10 Peptide cross-linking 81
2.11 Synthesis of standard 4-glutathionylthymidine 83
8
3. SYNTHESIS AND REACTIONS OF 4-THIO-5- 
BROMODEOXYURIDINE
3.1 Introduction 88
3.2 Synthesis of S4-BrdU 89
3.3 Manipulation of S4-BrdU 91
3.4 Reaction of S4-BrdUDNP with various nucleophiles 94
3.5 Reaction of S4-2,4-dnpBrdU with Na2S 95
3.6 Reaction with mercaptoethanol 97
3.7 Reaction with cysteine 99
3.8 Reaction with glutathione 101
3.9 Conclusions 103
4. STUDIES WITH DNA OLIGOMERS
4.1 Synthesis of oligonucleotides 105
4.2 Synthetic chemistry of unmodified oligomers 106
4.2.1 Bases 107
4.2.2 Sugar 107
4.2.3 Phosphoramidite 107
4.3 Automated oligomer synthesis 107
4.4 Synthesis of base-modified oligomers 109
(a) Preparation of base-modified nucleosides 109
(b) Conversion of base-modified nucleoside into phosphoramidite 109
(c) Incorporation of modified phosphoramidite into oligomers 109
4.5 Modification of protocol 110
9
4.6 HPLC purification 114
4.7 Characterisation of Ts pentamer 115
4.8 Incorporation of S4-BrdU into Oligomer 117
4.9 Activation of modified Oligomers 117
5. CONCLUSIONS AND FUTURE PRESPECTIVES
6. MATERIALS AND METHODS
6.1 Synthesis of 4-thiothymidine 123
6.1.1 Protection of 3' and 5' OH groups of sugar 123
6.1.2 Addition of triazole 124
6.1.3 Replacement of triazole by sulphur 125
6.1.4 Deprotection of 3 'and 5 'OH groups 126
6.2 Synthesis of TSDNP 126
(a) reaction with C1DNB 126
(b) reaction with FDNB 127
(c) HPLC monitoring of the reactions 127
(d) Isolation of the peak 127
6.3 Attempted Synthesis of S4-mononitrophenyl derivatives 128
6.4 Stability of TSDNP in aqueous solution 128
6.5 Reaction of t sdnp with various nucleophiles 130
6.5.1 Reaction with mercaptoethanol 130
6.5.2 Reaction with cysteine 130
6.5.3 Reaction with cysteine and glycine 131
6.5.4 Reaction with glutathione 131
10
6.6 Synthesis of Standards 132
6.6.1 Synthesis of 4-triazolothymidine 132
6.6.2 Synthesis of 2-hydroxyethylthymidine 134
6.6.3 Synthesis of 4-cysteinylthymidine 135
6.6.4 Synthesis of 4-glutathionylthiothymidine 136
6.7 Experimental for DTT 137
6.8 *H and 13C NMR data for modified thymidine nucleosides 137
6.9 HPLC conditions for S4-BrdU reactions 139
6.10 Chemicals and enzymes 139
(a) Monomers 140
(b) Synthesis of oligomers 140
(c) Synthesis of oligomers with modified base (Ts) 141
6.11 Purification of Oligomers 141
(a) Nensorb prep cartridge purification 142
(b) Procedure 142
(c) Sample preparation 142
(d) Cartridge preparation 143
6.13 HPLC conditions for Purification 144
6.14 Nucleoside composition analysis 144
7. BIBLIOGRAPHY 146
8. APPENDIX
l i
CHAPTER-/
INTRODUCTION
1. Introduction
1.1 The Cell
The basic units of all living organisms are called cells and all cells undergo the same 
basic biological processes. Cells have the following common main features:
• A plasma membrane which encloses and defines the cell and
• DNA which contains genetic information for biological processes
• Transcribing the information from DNA into RNA
• Translation of RNA to proteins
• Synthesising of proteins using the same set of 20 amino acids [1].
1.2 Cell Structure
A cell contains various organelles inside the plasma membrane such as the nucleus, 
mitochondria, endoplasmic reticulum, Golgi apparatus, lysosomes, peroxisomes, 
vacuoles etc. The nucleus is surrounded by a double membrane called the nuclear 
envelope, inside of which is DNA, the genetic material. The nuclear envelope 
differentiates the processes that occur inside the nucleus, DNA replication and 
synthesis of RNA from the processes that occur in the cytoplasm, translation of RNA 
to protein.
1.3 Organisation of DNA into Chromosomes
DNA is a long, un-branched, linear polymer that contains millions of nucleotides in 
non-random fashion; the genetic information is stored in the exact order of the 
nucleotides. The genetic code is written in words of three nucleotides. Only a small 
portion of the DNA codes for proteins and is called as coding DNA. Functions of non­
coding DNA are not fully understood but they contain sequences for other biological
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functions, such as patterns of DNA folding in each chromosome. DNA folding is not 
only important in packaging of the long DNA molecules in an orderly fashion but also 
the manner in which a region of the genome is folded in a particular cell can 
determine the activity of the genes in that region [2]. The DNA of human and also 
most of the eukaryotic cells, is tightly bound with specialised proteins called histones, 
which tightly pack the DNA and regulate its activity. There are five major types of 
histone proteins which are rich in positively charged basic amino acids and therefore 
readily interact with the negatively charged phosphate groups in DNA. Nuclear DNA 
associated with histone proteins is called chromatin. Large organised molecules of 
chromatin are called chromosomes. The chromosomes are not visible in non-dividing 
cells, even under electron microscope. During mitosis and meiosis (stages of cell 
division) the chromosomes condense and become visible even under a light 
microscope[3].
1.4 The Cell Cycle
The cell cycle starts with the cell preparing for the division by synthesising the 
necessary components for DNA replication. Cell cycle contains various phases -Gi,S 
(DNA synthesis), G2, and M (mitosis). Two check points exist, one between Gi and S 
and one between G2 and M as shown in Figure 1.1.
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Figure 1.1 adapted from Pharmacology by Rang [4]
Growth factors constitute the positive force that stimulates the cell to start on the 
cycle. These growth factors are a series of cyclins and cyclin-dependent kinases 
(cdks). The action of these cyclin/cdks is controlled by various negative factors. 
They include proteins that bind to the cdks and inhibit their action. Induction of these 
proteins is by various genes, for example the p53 gene and retinoblastoma gene (Rb) 
which are termed as ‘superbrakes’ on the cell cycle. In case of DNA damage, these 
inhibitors stop the cell cycle at checkpoint 1 as shown in Figure 1, allowing for repair
DNA is constructed from four main nucleotide building blocks. These building 
blocks contain, a phosphate group linked to a five-carbon-atom sugar group, which in 
turn is linked to an aromatic molecule that can be either a purine (double ringed) or a 
pyrimidine (single ringed). DNA contains the sugar deoxyribose, hence the 
nucleotides are called deoxyribonucleotides. DNA is built up of two purine
[4].
1.5 Chemistry of DNA
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containing nucleotides and two pyrimidine containing nucleotides. The purines of 
DNA are adenine and guanine. The pyrimidines are cytosine and thymine. Purine 
and pyrimidine bases containing sugar are known as nucleosides and are shown in 
figure 1.2.
j
OH H 
deoxyadenosine
H
HO
OH
HO—i
N N
OH
deoxyguanosine
OH H
deoxycytidine thymidine
Figure 1.2: Structure and numbering o f purine and pyrimidine nucleosides
Nucleotides of DNA are joined together by covalent bonds linking the phosphate 
group of one nucleotide to a hydroxyl group on the sugar of the adjacent nucleotide as 
shown in figure 1.3. These bonds are called phosphodiester linkages [5].
16
NH
5 ' end
Adenine
0 = P - 0 — CK
NH.
^  N Cytosine
P -O  CH.
NH Guanine
NH.
NH
Thymine
O
3’ end
Figure 1.3 A portion of DNA polynucleotide chain, showing the 3 -5 ' phosphodiester linkages
DNA is an anti-parallel double helix held together by hydrogen bonds between pairs 
of bases on the opposing strands. The base pairing is restricted: the purine adenine 
only base-pairs with pyrimidine thymine, while the purine guanine base-pairs with 
pyrimidine cytosine[5]. The restrictions are due to both steric hindrance and
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hydrogen bonding limitations. The helical nature of sugar-phosphate backbone does 
not allow two purines between the strands. Two pyrimidines fit between the strands 
but the bases would be too far away to form hydrogen bonds. Adenine donates 1H- 
bond and can accept another; thymine also can donate one and accept hydrogen in AT 
base pairing as shown in figure 1.4. Guanine can accept lH-bond and can donate 
2H when paired with cytosine, which can accept 2H-bonds and donates 1 hydrogen in 
the GC base pairing.
\\ 1X1 H ~ T
O H
Thymine-Adenine Base Pairing Cytosine-Guanine Base Pairing
Figure 1.4 showing hydrogen bonds in A T and GC basepairs
The hydrogen bonds not only provide the specificity but also stability to the double 
helix structure [5].
1.6 DNA damage
DNA consists of various functional groups such as exocyclic amino groups, double 
bonds, keto and hydroxyl groups all of which are reactive. So, DNA is constantly 
damaged by both internal and external agents such as ultraviolet (UV) light, ionising 
radiations, chemicals and diet. Approximately 70% of cancers in western populations 
can be attributed to diet and lifestyle [6].
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1.7 Damage to DNA by exogenous agents
1.7.1 Chemical Carcinogens
DNA is constantly damaged from exogenous agents both chemical and physical, 
which are commonly termed as environmental carcinogens. For both, the chemical 
reaction giving rise to DNA damage can be characterised as an electrophilic attack , 
upon a tissue nucleophile [7]. Chemical attack on guanine is the most significant type. 
The chemical changes induced to guanine are known to interfere with base-pair 
recognition during replication. Environmental carcinogenesis was reported in as early 
as 1775 and involved tumour induction in chimney sweeps exposed to polycyclic 
hydrocarbons in soot [6]. Other chemicals such as dimethylnitrosamine, which was 
used as a specialised industrial solvent in the 1930s, was implicated in liver damage in 
exposed workers [8].
1.7.2 Diet
The accidental discovery of dimethylnitrosamine as a carcinogen was a major 
breakthrough. This discovery was interesting because it not only led to the detection 
of an industrial carcinogen but also to a new class of carcinogen, N-nitrosamines. 
Subsequently, the N-nitrosamines were identified in a number of consumer items 
from beer, to tobacco smoke and cosmetics [9].
c h 3
0 = N  N
CH3
fig  1.5 NyN-dimethylnitrosamine
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Nitrosamines were also found to be formed in the acid environment of the stomach 
with primary and secondary amine ingestion which are found in high levels in fish, 
and of sodium nitrite, which is found in salted fish as a preservative. The high 
incidence of gastric cancer in Japan and Iceland was linked to their diet which has 
salt-preserved fish as a major constituent. Epidemiological data suggests that red and 
processed meat intake also increase the risks of colorectal cancer. This might be due 
to the formation of heterocyclic amines formed while cooking the meat [10-13].
1.7.3 Physical Carcinogens
Ionising radiations and ultraviolet radiation (UV) can be considered as physical 
carcinogens. Although they differ in their chemical reactions both classes of physical 
carcinogens produce DNA damage which, as with the chemical carcinogens, can lead 
to mutations. DNA can be directly damaged with ionising radiations by causing 
single and double strand .breaks in the helix and can also induce indirect damage by 
radiolysis of water to produce free radicals[14]. UV radiation has less energy when 
compared to IR and cannot produce ions. UV radiation can be absorbed by the DNA 
bases and is sufficient to induce chemical reactions. The most common of these 
reactions are between two thymidines in the DNA helix and results in the formation of 
cyclobutane-linked thymine dimers as shown in Figure 1.5 [15].
I
H
I
H
Figure 1.6 Cyclobutane linked dimer formation in adjacent thymidines
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UV could also damage purine bases that might lead to potent toxic and mutagenic 
lesions [16-19]. Formamidopyrimidine derivates have been identified among other 
purine photoproducts [20]. These derivatives may result in the obstruction of DNA 
polymerase and if not repaired can give rise to mutations.
1.7.4 DNA damage by free radicals *
Inside the cell a small fraction of oxygen is converted into superoxide as a by-product 
during the cellular metabolism of oxygen to water inside the mitochondria[21]. This 
superoxide may be converted into various reactive oxygen species (ROS) like 
hydroxyl radicals ( OH), H2O2 etc via various chemical and biochemical processes. 
Most of the cells possess defence mechanisms against the potential harmful effects of 
ROS. These defence mechanisms include catalase which converts H2O2 into water 
and oxygen and superoxide dismutase which converts its substrate, superoxide into 
oxygen and hydrogen peroxide [22]. The majority of DNA lesions induced by 
oxidative metabolism are single, but multiple lesions known as tandem lesions may 
appear on adjacent nucleotides [23].
Even though DNA is chemically damaged by various agents the damage of DNA 
itself is not a mutagenic event. Replication of DNA and cell division is necessary to 
convert the damage to an inheritable change in the DNA. In addition to chemical 
damage to DNA. spontaneous mutations can occur directly as a consequence of errors 
in replication [15]. Spontaneous DNA damage is a frequent event but as 
approximately 97% of DNA is non-coding in the human genome many base changes 
do not give rise to deleterious mutations [15].
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1.8 DNA Repair
As discussed above, DNA is constantly exposed to chemical damage, both 
endogenous and exogenous, throughout evolutionary time. To check the genome for 
damage and/or repair, genes such as p53 have evolved. Other genes exist whose 
function is to repair errors introduced during the process of replication [15]. 
Mechanisms of repair differ according to the type of DNA damage. Thymine dimers 
are formed as a consequence of UV radiation. In this case, the whole stretch of DNA 
is removed and re-synthesised using the opposing strand as a template. Alkylated 
bases such as 0 6-methylguanine can be directly removed without breaking the
phosphate backbone. Single strand breaks can be directly repaired [15, 24]. DNA
\
double strand breaks are the only type of damage that cannot be repaired. In this case 
because both the strands are damaged, the cell has no unmodified template that can 
provide the information necessary to repair the damaged strands. This type of damage 
could lead to cell death depending on the site of double strand break or, this could be 
of significance to the carcinogenic process, chromosome breakage and recombination 
with resulting activation or inactivation of crucial genes[15]. Defects in these repair 
processes play a vital role in the carcinogenesis by increasing the rate of mutations. 
Several genetically inherited diseases which give rise to cancers have their origin in 
defects of DNA repair capacity. These include ataxia-telangiectasia, in which cells 
are sensitive to X-rays [25] and Xeroderma pigmentosum which is sensitive to UV 
[26]. BRCA1 is the gene essential for repair in response to DNA damage in breast 
cancer [27]. One of the most frequently mutated genes in human solid tumours is p53 
which has been called “the guardian of the genome”. This gene not only has the 
functions of monitoring the integrity of genome but also has the capacity to delay
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replication until the repair has been completed or if the damage is extensive it induces 
a series of events leading to programmed cell death by a process called apoptosis [28].
1.9 Cancer Biology:
Cancer is defined as a disease in which there is an uncontrolled multiplication and 
spread of the body’s own cells. Incidence of human cancers increases with age. 
Cancer is one of the major causes of death in the developed nations. One in five 
people in Europe and North America die of cancer. Mutations in the genes have two 
distinctive consequences:
(a) Inappropriate expression or activation of genes
(b) Functional inactivation of the genes or its protein product
According to American Cancer Society two types of genes play a role in the 
development of cancer: Oncogenes and Tumour Suppressor genes. Oncogenes are 
mutated form of genes that cause normal cells to grow out of control and cause 
cancer. Tumour suppressor genes are normal genes that regulate cell division, repair 
DNA mismatches and bring programmed cell death (apoptosis). When tumour 
suppressor genes are mutated, cells can grow out of control leading to cancer. 
Oncogenes are involved in signalling pathways which stimulate proliferation and the 
tumour suppressor genes code for proteins which normally act as checkpoints to 
proliferation or cell death. The following five major pathways must be activated or 
inactivated for the cell to become malignant.
• Development of independence in growth stimulatory signals
• Development of refractory state to growth inhibitory signals
• Development of resistance to apotosis
• Development of an infinitive proliferative capacity
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• Development of angiogenic potential (capacity to form new blood vessels and 
capillaries) [15].
1.10 Skin Cancer
Continuous exposure to UV radiation damages DNA of the exposed skin and might 
lead to cancer[15]. In the Northwest Europe the incidence of skin cancer is almost 
equal to that of lung or breast cancer, but in the U.S the skin cancer is the most 
common type[29]. Skin cancer could be classified into three main types: the most 
common type basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and 
cutaneous malignant melanoma (CMM) [29]. CMM (arising from melanocytes) is the 
cause of majority of the deaths from skin cancer though it is less common than BCC 
or SCC (arising from keratinocytes). These two are less aggressive and can be cured 
with relatively high success but if neglected, can become invasive. Skin cancers can 
be identified early in their development because they occur on the body surface which 
greatly enhances to the success of their therapy[30].
1.11 Cancer treatment:
The best form of treatment is prevention. Changes in lifestyle such as smoking 
control and dietary habits are necessary. Detecting the cancer early is also important. 
Treatment of cancer is generally based on the removal and/or killing of the tumour 
cells while minimising the side effects to normal cells.
Three main approaches are followed to treat the established cancer: surgical 
excision, irradiation and chemotherapy. The role of these approaches depends upon 
the type of tumour and the stage of its development. Chemotherapy is used as a 
main method for only certain types of cancers [4]. But it is used as an adjunct to
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surgery or irradiation for many types of tumours. Many other approaches such as 
immunotherapy, angiogenesis inhibitors, gene therapy, and use of biological response 
modifiers (e.g. interferons, haemopoietic growth factors, etc) are under extensive 
investigation. Chemotherapy poses a problem because cancerous cells and normal 
cells are very similar in many respects and it is difficult to find general, exploitable, 
biochemical differences between them. The major difficulty in the use of cancer 
chemotherapy is that a tumour is usually far advanced before it is even diagnosed [4]
1.12 Drugs used for cancer chemotherapy
Most anticancer drugs act in S phase, the phase of cell cycle in which DNA synthesis 
occurs. Some act in M phase, where chromosomes are condensed and nucleus and 
cytoplasm divide. But some have complex actions in the cycle. Cell cycle 
progression is regulated by positive and negative forces[31].
The main anticancer drugs could be categorised as follows:
• Cytotoxic drugs:
As the name suggests these drugs induce toxicity to the cancerous cells by different 
mechanisms as shown in figure 1.6 leading to cell death. These drugs can be further 
categorised into
-alkylating agents and related compounds: these agents form covalent bonds with 
DNA and interfere in its replication
-antimetabolites: these agents block the metabolic pathways involved in DNA 
synthesis. Antimetabolites are the structural analogues of naturally occurring 
compounds that interfere with the synthesis of nucleic acids. They can be further 
classified into antifolates, purine analogues and pyrimidine antimetabolites.
-cytotoxic antibiotics: agents of microbial origin that prevent mammalian cell division 
-plant derivatives: most of these affect microtubule function
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• Hormones:
These agents mostly comprise of steroids such as glucocorticoids, oestrogens and 
androgens. These drugs mostly suppress hormone secretion or antagonise hormone 
action.
• Miscellaneous Agents:
Drugs that do not fit into the above categories.
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1.13 Carcinogenic Cancer Chemotherapeutic Agents
Many cancer chemotherapeutic agents show their pharmacological activity by causing 
DNA damage. Patients surviving the therapy with these agents are at high risk of 
iatrogenic cancer [32]. Even the radiotherapy has the same implications but the 
localised nature in comparison to systemic therapy with chemotherapeutic agents, 
limits the overall risk of secondary cancer. Alkylating agents such as 
cyclophosphamide bring out their pharmacological action by reacting with DNA. 
This action is similar to the carcinogens as discussed previously. Other class of 
compounds include antibiotics such as, doxorubicin that interact non-covalently with 
DNA and induces DNA damage by free radical mechanism [15]. So, paradoxically, 
most of the available cancer chemotherapeutic agents are carcinogenic themselves.
1.14 Nucleosides and analogues as drugs
Uptake of nucleosides into the cells is mediated by nucleoside transporters (NTs) 
[33]. Specialised cells such as enterocytes, bone marrow cells and certain brain cells 
lack de novo synthesis pathways [34]. These cells salvage nucleosides from the 
extracellular milieu for the production of nucleotides to use in RNA and DNA 
synthesis. Nucleotides play an important role as intermediates for many essential 
cellular biosynthetic pathways. Other key roles of nucleotides include 
neurotransmission [33] and regulation of cardiovascular activity [35] and as signalling 
molecules [36]. Nucleoside kinases present inside the cells mediate the 
phosphorylation of nucleosides to nucleotides [37]. Apart from these functions 
nucleosides are also used as drugs for treatment of some conditions for example 
adenocard (unmodified adenosine) is used as a drug to slow tachycardia (a condition 
where heart rate increases). Also naturally occurring nucleosides and nucleotides
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have been chemically modified for more than 50 years and various analogues have 
been synthesised to exploit mostly their antiviral and anticancer properties[38-41]. 
The cellular uptake of anticancer and antiviral nucleoside drugs is similar to that of 
natural nucleosides i.e. mediated by nucleoside transporters (NTs)[33]. The 
modifications are of two types:
• sugar modified nucleosides
• base modified nucleosides
The sugar is usually modified at 2’ or/and 3’ or/and 5’ positions [42-44]. Sugar 
modified nucleosides are mainly used as antiviral and anticancer agents for example 
Zidovudine (AZT) which is used in the treatment of AIDS is modified by insertion of 
an azide group at the 3’ position in the sugar of thymidine [45-47]. Usually base 
modified nucleosides are synthesised by replacing oxygen or hydrogen atom of uracil, 
thymine or guanine with a suitable leaving group and replaced by the desired atom or 
group[48] like for example 5-fluorouracil (5-FU). In this drug the hydrogen atom at 
the fifth position of uracil was substituted by fluorine atom. The cellular toxicity was 
attributed to the presence of fluorine. 5-FU is metabolised in a similar manner to 
uracil. This was attributed to the fact that atomic radius of fluorine is similar to that 
of hydrogen (1.35A compared to 1.2A) and that the bond between the carbon and 
fluorine is extremely stable. 5-Fluoro-2’-deoxyuridine (FdUrd), the corresponding 
deoxyribonucleoside derivative of 5-FU also has chemotherapeutic activity. 5-FU 
and FdUrd, along with other agents are now the most widely used drugs in the 
treatment of advanced colorectal cancer as well as many other cancers including 
breast, head/neck carcinomas [49-51].
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1.15 Sulphur modified nucleosides
Sulphur modified nucleosides are an important class of modified nucleoside 
analogues. These sulphur modified analogues can be classified into two kinds;
• sulphur modification in the sugar
• sulphur modification in the base
It was reported that the replacement of oxygen with sulphur in the sugar of thymidine 
and deoxycytidine gave nucleosides antiviral and antitumour properties [52, 53]. 
Base modified analogues are also used for therapeutic activities, for example, 6 - 
mercaptopurine has been used since the 1950’s for the treatment of acute leukemia 
[54] and azothioprine is used as an immunosuppressant.
Apart from their therapeutic activities a number of other applications have been 
reported for thiopyrimidine and thiopurine nucleosides and nucleotides. For example 
thio derivatives of adenosine are used as affinity labels for pyruvate kinase [55, 56] 
and photo-affinity label of DNA polymerase I Klenow fragment [57]. Thioadenosine 
and its phosphate derivatives were also used as intermediates in the synthesis of 
various photo-reactive nucleosidic, nucleotidic and oligonucleotidic probes. Other 
thioadenosine derivatives such as 8 -[(4-azidophenacyl)thio]adenosine 5’-triphosphate 
were used as a photo cross-linking agents[58]. 4-thiouridine is present as a natural 
constituent of t-RNA and is used as an intrinsic photo-label in the study of nucleic 
acids [59, 60]. Photo cross-linking ability of 4-thiopyrimidine and 6 -thiopurine 
nucleosides has been used to study the three-dimensional interactions between RNA- 
RNA or RNA-proteins. Thiopurines and thiopyrimidines are activated selectively by 
UVA light (330-350nm) and the specific contacts were mapped using photo cross- 
linking [60-64]. Sulphur modification of thymidine on the 5-methyl group could be 
achieved by 5-chloro derivative and the 5-thiomethyl derivatives prepared from this
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intermediates have efficient anti-herpes activity [65]. Apart from these uses, sulphur 
modified nucleosides are also used as tools in studies of protein or nucleic acid 
structure and functions. The thionucleobases are used as intrinsic photolabels to 
probe the structure in solution of folded RNA molecules and to identify contacts 
within nucleic acids and between nucleic acids and proteins, in complex nucleoprotein 
assemblies. The thiobases absorb light at wavelengths longer than 320 nm and thus 
can be selectively photoactivated. The photoadducts formed are studied. The 
photocrosslinking potential of thionucleosides inserted in nucleic acid chains has been 
used to probe RNA-RNA contacts within the ribosome. These can also be used as 
anti-sense modulators of gene expression [48].
1.16 Thiopurines as drugs
The cytotoxic thiopurine agents 6 -mercaptopurine, 6 -thioguanine and azathioprine are 
used as prodrugs and must be metabolised before they can interfere with the synthesis 
of DNA [6 6 ]. The presence of a reactive thiol group was attributed to their cytotoxic 
and immunosuppressive properties. The activity of thiopurines is via the 
incorporation into DNA as thioguanine nucleotides or inhibition of de novo purine 
synthesis by methyl thioguanine nucleotides [67]. 6 -Mercaptopurine is widely used in 
primary treatment of childhood leukaemia and as an investigational agent for the 
treatment of Crohn’s disease and the related gastrointestinal disorders. 6 - 
Mercaptopurine is catabolised by xanthine oxidase to the inactive metabolite 6 - 
thiouric acid. A second catabolic pathway involves thiol methylation by the enzyme 
thiopurine methyltransferase which converts 6 -thioinosine monophosphate into 6 - 
thioinosine monophosphate [6 8 , 69].
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Azathioprine 6-mercaptopurine 6-thioguanine
Fig 1.8 Chemical structures o f thiopurines used for anti cancer therapy
Azathioprine molecule contains two main moieties as shown in figure 1.8, a 
mercaptopurine and imidazole derivative. It is metabolised to form mercaptopurine 
and methyl-4-nitro-5-imidazole derivatives are metabolised by suplhydryl (SH) and 
amino group (NH) containing compounds like cysteine [70, 71]. The first step in the 
nucleophilic attack of the COO(-) of cysteine on the C(5i) atom of the imidazole ring 
of azathioprine molecule [70, 71]. Azathioprine is used as an immuno suppressant 
along with other drugs for solid organ transplantation. This dmg is also under 
investigation for the treatment of rheumatoid arthritis, vasculitis and dermatological 
disorders[72]. 6 -thioguanine has been used as a therapeutic agent in the treatment of 
cancer since the early 1950s[54]. Similar to azathioprine and 6 -mercaptopurine, 6 - 
thioguanine also requires activation to 6 -thiodeoxyguanosine 5’-triphosphate through 
metabolic pathways before i f  s incorporation into DNA[73, 74].
1.17 Thiopyrimidines as drugs
Unlike thiopurines not many thiopyrimides have been developed as drugs even 
though many derivatives have been synthesised for more than 50 years. Antiviral 
activity of 2-thiopyrimidine and its 5-halogenated derivatives has been previously 
reported[75]. Anticancer activity of these compounds has not been thoroughly
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investigated. However incorporation of 4-thiothymidine (Ts) into DNA and the 
synergistic effect of UVA light in sensitising the human cancerous cells to a very low, 
non lethal UVA doses have been reported[67]. Cellular incorporation and photo 
chemical properties of 4-thio- 5-bromo-2’-deoxyuridine (S4-BrdU) have also been 
reported [76].
Data available for most of the thiopyrimidines, for example Ts and S4-BrdU suggests 
that they are not toxic to cells over a range of concentrations unlike thiopurines. 
Cellular incorporation reports have suggested that Ts was a substrate for thymidine 
kinase (TK) but not for thymidine phosphorylase (TP) and the incorporation of Ts 
into DNA is mediated by thymidine salvage pathway. It was also reported the Ts was 
not very toxic when incorporated into the cells. In another report Massey et al[67]
o
have demonstrated T to be a weak mutagen when compared to other thiopurines. It 
replaces thymidine when incorporated into the DNA. They have also reported that Ts 
generally codes to direct the incorporation of adenine (A) during replication. These 
properties make Ts an ideal candidate for cellular incorporation and further 
manipulation.
S
NH
HO.
OH
Figure 1.9: Thiopyrimidines:Structure of I s
The substitution of oxygen by sulphur at position 4 as shown in Figure 1.8 shifts the 
absorption spectrum from 267nm to 335nm. This property makes it easier to identify
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it in the presence of the other nucleosides which have a maximum absorption around 
260nm [77]. Thiopyrimidine also sensitises cells when exposed to UVA light. Other 
properties such as cross-linking of DNA could also bring about cell killing.
1.18 Cross-linking
As mentioned in figure 1.6 the cytotoxic action of the alkylating agents such as 
mitomycin and cisplatin is due to the formation of interstrand cross-links within the 
DNA strands[4]. Apart from these alkylating agents many other possible anticancer 
drug candidates also exert their cytotoxic action by forming cross-links. These cross­
links are non-specific leading to hazardous side effects. As mentioned earlier guanine 
is the major site of modifications for most of these drugs[78]. Moreover formation of 
mismatch is the major disadvantage with the other drugs if used for this purpose. The 
‘not very toxic’, weak mutagenic nature and coding exclusively for adenine makes 4- 
thiothymidine an ideal candidate for cross-linking.
1.19 DNA-Protein cross-linking:
DNA and protein interactions are very important in the cellular processes from DNA 
replication to gene regulation [79]. These interactions are vital for the survival of a 
living organism. For example, as mentioned earlier, cells are under constant threat by 
DNA damaging agents like chemical and physical carcinogens. When the DNA 
damage occurs a number of biochemical signalling pathways are activated to repair 
the damage. The process of repair is carried out by the proteins which interact with 
the DNA [80]. Interestingly, purposeful cross-linking of proteins to DNA interrupts 
DNA metabolic processes such as replication, repair, recombination, transcription and 
chromatin remodelling. The effects of agents that cause DNA-protein cross-links
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(DPCs) have been investigated[81-83]. DPCs physically block the progression of 
replication or transcription complexes and prevent access of proteins required either 
for synthesis along the template strand, for transcription, or for repair recognition 
and/or incision. By anchoring to the chromatin they may also affect all of these 
processes and prevent its remodelling [84].
Several methods have been developed for cross-linking of proteins to DNA but only a 
few such as photo cross-linking and chemical cross-linking were successful. The 
principle involved in the photo cross-linking technique is that an agent is irradiated 
with a suitable light source and the level of cross-linking is determined [85-88]. The 
agents used for photo cross-linking include azide derivatives, halogenated bases and 
thio-bases etc [89-92]. Non specificity of the reaction is the main disadvantage with 
photo-cross-linking[8 8 ].
Chemical cross-linking reactions are either nucleophilic or electrophilic substitutions 
but could be non specific because the DNA has many nucleophilic sites such as keto, 
exocyclic amino, double bonds and hydroxyl groups. Xu and others [8 8 , 93] have 
reported a method for site specific and chemical cross-linking of 
oligodeoxynucleotides containing 6 -methylsulphoxypurine with cysteine and peptides 
containing cysteine. In this method the author achieved the specificity of the reaction 
by creating an electrophilic site with a synthetic fragment of the DNA (pentamer). 
Creating an electrophilic site that is specific for an incoming nucleophile in the 
cellular DNA could be a tedious and laborious process and probably practically 
impossible to achieve. This is because, as discussed earlier DNA has many reactive 
sites. The post-synthetic approach [85] is another strategy in which a monomer 
containing a leaving group is incorporated into the oligomer which is then replaced by 
suitable nucleophiles to obtain the desired product. 1,2,4-Triazolo group was
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introduced as a leaving group and manipulation was done by various thio- 
nucleophiles. This approach also has similar disadvantages like that of the chemical 
cross-linking method where synthesising DNA with a suitable leaving group and 
introducing into the cellular DNA might not be feasible.
1.20 Aims and approaches of the current work.
In this project combination of both the approaches would be followed. Two thio 
modified nucleosides were selected for the purpose of this work. The primary 
objective in selecting these nucleosides was that, they were proven to be not cytotoxic 
.when incorporated into the cells. 4-Thiothymidine and 4-thio-5-bromodeoxyuridine 
were chosen. The fact that 4-thiothymidine and 4-thio-5-bromodeoxyuridine could 
be easily incorporated into the cellular DNA with little toxicity [67] and that the thio 
group could be used for further modifications [94] has prompted us to follow this 
approach. Previously the thio group of modified nucleoside was used as a tool in the 
areas of molecular biology and cancer research [95]. The thiol group in 
oligonucleotides was also used for the synthesis of other modified oligonucleotides by 
post synthetic modification [96]. So the thio group of 4-thiothymidine and 4-thio-5- 
bromodeoxyuridine could be used as site specific chemical cross-linker of the DNA. 
In order to achieve this, first the thiol is modified by a reasonably stable and good 
leaving group and then cross-linked by amino acids and peptides containing thiols. 
Subsequently, the modified nucleoside(s) would be incorporated into the DNA and 
the cross-linking with the DNA strand would be explored with the same amino acids 
and peptides containing thiols. Then a protein would be chosen to study the 
interaction between the DNA and protein.
36
CHAPTER 2
SYNTHESIS AND REACTIONS OF 4-THIOTHYMIDINE
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2 Synthesis and Reactions of 4-Thiothymidine
The synthesis of Ts was first reported by J.J. Fox et al in 1959 [97]. The synthetic 
procedure has been simplified and reported by various authors since then [98] [99]. 
Physically 4-thiothymidine is yellow coloured powder with chemical formula of 
C10H14N2O4S and the formula weight is 258.30. It is structurally similar to the 
pyrimidine nucleoside thymidine except for the oxygen at C4, which has been 
replaced by sulphur. The reported protocol [98] was used for the synthesis which 
involves four steps as shown below.
2.1 Synthesis of 4-thiothymidine 
Step-1
The first step involves protection of 3’ and 5’ OH groups of sugar with trimethylsilyl 
groups as shown in Scheme 1. Thymidine (1) was suspended in THF and reacted with 
trimethyl chlorosilane in the presence of triethyl amine to give 3 \5 v-0-bis-(trimethyl 
silyl)-thymidine (2 ).
O O
SiMe3 Et3N
*0 THF; Ice bath, 2.5 hrs 
Me3Si—O.
OOH 1
(1)
SiMe3
(2)
Scheme 1 Protection o f  3 ’ and 5 ' OH o f thymidine 
The OH groups are highly reactive. So 3 ’ & 5' OH 
groups are protected with SiMe3
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Step-2
2 in acetonitrile was treated with 1,2,4-1H triazole in the presence of triethylamine 
and phosphorous oxychloride to give 3\5'-0-bis-(trimethyl silyl)-4-trizolothymidine
(3) as shown in Scheme 2.
The key intermediate in this reaction is phosphoryl-rns-triazolide which is formed by 
the reaction of phosphorous oxychloride and l,2,4-(lH)-triazole in the presence of 
triethylamine in acetonitrile. Triethyl amine is added in 2:1 molecular ratio in the 
beginning of the reaction and is not only used to neutralise the formed HC1 but also to 
abstract a proton from 1-N of triazole. The phosphorous in the formed phosphoryl- 
m’s-triazolide then reacts with the oxygen at C4 of thymidine to give 3 \5 v-0-bis- 
(trimethylsilyl)-4-phosphoryl-rns-triazolothymidine. The lone pair of electrons on the 
nitrogen of triazole is then set up for attack at C4 to form 3 \5 V -O-bis-(trimethylsilyl)- 
triazolothymidine (3) [100-102]
Triazole,E t^N ; PO C I3
0
SiMe3
(2)
1 9
SiMe3
(3)
S ch em e 2 T riazo la tion  o f  C4 o f  thym id in e  
This reaction  takes ap p ro x im a te ly  16  h ours f o r  com pletion
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Step-3
3 in acetonitrile was treated with thiolacetic acid to give 3 \5 v-0-bis-(trimethylsilyl)- 
2" -deoxy-4-thiothymidine (4).
NH
c h 3c n , c h 3c o s h
Ice bath, O.N
(3) (4)
Scheme 3 Thiol group formation at C4 
Triazolo group is replaced with sulphur. A t this 
stage 3 ’ & 5' OH groups are still protected
Protonation of the triazolo group affords a thioacetate ion which can then attack at C- 
4. Subsequent loss of the acetyl group probably occurs because the thio-keto function 
is more stable than 4-S-acetyl derivative.
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Step-4
The trimethylsilyl groups are unstable in the presence of acid and 4-thiothymidine (5) 
is produced in high yield (more than 90%) by treatment of 4 with acetic acid in 
methanol.
NH NHc h 3c o o h , m e o h
Room temp
HO,
OH
(4) (5)
Scheme 4 Addition o f acetic acid deprotects 3' & 5' hydroxyl groups
Miah et al [99] have simplified the procedure and in the final step performed silica gel 
column chromatography to obtain the pure compound. This method has been further 
simplified by us without having to perform column chromatography for purification 
and the compound obtained was highly pure when checked on HPLC (see chapter 5- 
materials and methods section for detailed procedure.
2.2 Modification of 4-thiothymidine
2,4-Dinitrophenyl (DNP) is a stable and good activating moiety for leaving groups 
allowing heteroatoms to be replaced by nucleophiles [103]. Syntheses of 2,4- 
dinitrophenyl-containing thiopurines as phosphoramidites such as 6-(2,4- 
dinitrophenyl)-thiopurine and 2-amino-6-(2,4-dinitrophenyl)-thiopurine and their
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incorporation into oligonucleotides have been reported [103-105]. However this 
approach has not been reported for pyrimidines such as thiothymidine and this was 
chosen as the next stage.
2.3 Introduction of 2,4-dinitrophenyl group onto 4-thiothymidine
5 was treated with 2,4-dinitrohalobenzenes (l-Chloro-2,4-dinitrobenzene and 2,4- 
fluorodinitrobenzene (Sanger reagent)). The reaction was carried out at room 
temperature at pH 9.5 and monitored by HPLC at different time intervals.
NO
NH
RT; pH 9.5
(X=C1, F)HO. HO.
OHOH
5 6
Scheme 5 formation of Tsdnp from the reaction of Is  and halodinitrobenzenes
Possible reaction mechanism
NO; NO;
OoN
NH
A 0 + HF
HO.
OH OH OH
6
Scheme 6 Reaction (f (5) with FDNB
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In the following reactions the molar ratio of Ts to reagents was 1:1. A typical HPLC 
profile was shown in figure 2 .1 .
a)
SDNP
I " " ! 1 " 1! " " ! " " ! " " ! " " ! " " ! " " ! " " ! " " ! " " ! " " ! "
2 4 6 8 10 12 14
Minutes
Figure 2.1: (a) HPLC trace o f reaction o f T6 with FDNB and b) HPLC trace o f reaction o f T  with
CIDNB, the reagent peaks were not shown.
The product (TSDNP) is formed at a much quicker rate when FDNB was used.
After lhour a new peak of TSDNP, putatively, was observed at the retention time 13.5
minutes in figure 2.1 (a) but not in figure 2.1 (b). Peak at retention time 7.4 minutes
is that of starting material 5. The reaction was left at room temperature and monitored
by HPLC after 24 hours (profile not shown) and 48 hours (shown in figure 2.2).
a) iSDNB
2 4 6 8 10 12 14
b)
i SDNP
....i1 . 1 1 1 1 
4
. 1111 i i , n . . , . . . I , . , , i . i , 111
14
'11i . i 
10
1 > i'
2 6 8
Minutes Minutes
Figure 2.2: HPLC trace o f reaction o f V  with 
(a) FDNB after 48 hours, (b) CIDNB after 48 hours 
Most o f the starting material was converted to product when FDNB was used as a reagent
after 48 hours
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After 48 hours most of 5 was converted into a new peak in Figure 2.2 (a). In Figure 
2.2(b) 5 was converted into a new peak with the same retention time and UV 
spectrum. So the same product was observed with both reagents. The new peak has 
the UV spectrum as shown in figure 2.3
250
14
239
300 350250
nm
Figure 2.3 UV spectrum o f  7 ^ (2 ^  336) and ^^(Xmax 314nm) 
j 6DNP can be easily separated form T  by UV difference
The reaction was thiol specific as no reaction with 1 was observed under the same 
conditions (Figure not shown). The same product was observed at a faster rate when 
2, 4-dinitrofluorobenzene (FDNB or Sanger reagent) was used (explain why). FDNB 
was therefore used in subsequent reactions.
The reaction was explored further and a more rapid and greater increase in the 
formation of 6  was observed when excess of phosphate buffer was added to the 
reaction mixture. This could be due to the neutralisation of HF produced during the 
reaction.
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rjiSDNP
rjpS
...JlAJV . .
4
M 1 " 1 | 1 
6
i | i ' i i i . . . . | i i i . | i i i i 
8 10
Minutes
11 i i i 11 . i i | . i 
12
I l | II , 1
14
Figure 2.4: HPLC trace o f addition o f excess phosphate.
Most o f the starting material (T ) was converted to product (JSDNP) after O.N
6  has a longer retention time and can be well separated from the starting material 4- 
thiothymidine and from thymidine. A typical HPLC separation profile is shown in 
Figure 2.5.
SDNP
Minutes
Figure 2.5 can be well separated from starting material (T ) and Thymidine (T°)
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As shown in the figure 2.5, 6  could be easily separated and can be isolated from 
compounds (1) and (5) and the isolated peak of 6  shows a high degree of purity on 
HPLC as seen in figure 2.6.
(b)
L1.5
250.8
314.7
260220 340 380300
Figure 2.6 (a) Isolated peak o f JSDNP ( b) UV of i SDNP 
Phenomenon Synergi Max 250 X 10 mm column was used for the isolation o f
Mass spectral data of the new peak was obtained and it was tentatively assigned as S4-
2,4- dinitrophenylthiothymidine or 6 . The observed fragments were 424 M+, 423 
(M+-H)+ and 425 (M+H)+.
A Similar kind of approach has been reported by Xu [94] with thiopurine nucleosides. 
It was reported that unwanted 6 -thiopurine analogues were formed through hydrolysis 
when 6-(2,4-dinitrophenyl)-thiopurine was used. Xu attributed this to the fact that 6 - 
(2,4-dinitrophenyl)-thiopurine has two potential sites of nucleophilic attack i.e. purine 
C- 6  resulting in the displacement of the dinitrophenylthio group and the C-l carbon of 
the dinitrophenyl group resulting in displacement of the 6 -thiopurine group. Both 
pathways involve displacement of good leaving groups. To overcome the unwanted 
formation of thiopurine during nucleophilic substitutions, Xu replaced the strongly
46
electron-withdrawing dinitrophenyl by less electron-withdrawing alkyl groups. 
However, this reduced the good leaving capability of dinitrophenylthio significantly. 
Nyilas and Chattopadhyaya [106] have introduced mono-nitrophenyl on the C4 
oxygen of 2’-0-methyl-cytidine and other derivatives. Also Miah et al [99] have 
reported that nucleosides containing mono-nitrophenyl groups on oxygen were stable 
and could be readily replaced. So instead of an alkyl group a mono nitro reagent was 
tried in this experiment to reduce the strong electron-withdrawing effect of dinitro. It 
was also presumed that the good leaving capability of nitrophenylthio group is 
retained.
So, reaction with l-fluoro-2-nitrobenzene and l-fluoro-4-nitrobenzene under the same 
reaction conditions were monitored for 48 hours. No product was observed and a 
typical HPLC profile was shown in Figure 2.7 for overnight reaction.
(b)
1F2NB 1F4NB
4 8 12 1612
Minutes Minutes
Figure 2.7 HPLC traces for overnight profile o f Is  reaction with (a) 1F2NB and (b) 1F4NB 
No new peaks were observed after leaving for overnight.
Since no new peaks were observed, both fluoro-2-nitrobenzene and fluoro-4- 
nitrobenzene were deemed unsuitable reagents and the product with FDNB i.e. 6  
would be used for further manipulations.
Knowledge of the hydrolytic stability of 6  would provide useful information for its 
further manipulation with various nucleophiles. So the stability of 6  was studied.
2.4 Stability studies of TSDNP:
In the aqueous solution TSDNP was slowly hydrolysed to two new peaks. Highlights 
of the studies were, when pH of the solution was kept between 4 and 9 at room 
temperature, less than 5% of TSDNP was hydrolysed after 24 hours. The compound 
seemed to be very stable when left in pH 6 - 8  for 24 hours. At pH 7 and 8 , the 
hydrolysis was still very slow and over 60% of TSDNP remains unchanged even after 9 
days. At pH 10 a quarter of TSDNP was hydrolysed in a day as shown in figure 2.8.
'SDNP
2 6 10 14 18
Figure 2 .8 :1M concentration o f phosphate buffer pH  10 was added to 
and the solution was injected on HPLC after 24hours
The complete studies are represented graphically in Figure 2.9.
48
pH effects on the stability of (6)
120
100
(3JD
9 days
u
4 6 85 7 9 10
pH
Figure 2.9 Buffers o f pH  4 tolO were added to compound (6) and the effect was monitored on HPLC 
at different time intervals. Effect after a day and 9 days was graphically represented.
As the compound was hydrolysed at pH below 6  and at pH above 8 , thus it is clear 
that the compound TSDNP (6 ) undergoes both acid and base hydrolysis as shown in 
Scheme 7.
2.4.1 Characterisation of new peaks
The new peaks were characterised to be that of 1 and 2,4-dinitrothiophenol (7) by 
comparing with the retention time and UV of the standards. The acid and base 
hydrolysis of (6 ) is illustrated in Scheme 7.
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NH
OH '
HO HO
OH OH
(6) (1)
0 2N. JOrNO;
(7)
Schem e 7: h ydro lysis o f  S -2 ,4 -d in itroph en yth io th ym id in e
j ,sdnp  un([erg 0es both a c id  an d  base  h ydro lysis g iv in g  the sam e p rodu cts
Interestingly 4-thiothymidine (5) was. not observed among the products which would 
suggest that 6  undergoes only nucleophilic attack at C-4 (a-attacking route) and not C- 
1 of the aromatic ring (p-attacking route) as reported by Xu [94] for dinitrothiopurines 
(see Scheme 8 ).
Nu 9
NO;
Nu
a,p  attacking route
dR
a  attacking route
Scheme 8: (6) undergoes os-attacking route only whereas 
dinitrophenyl thiopurine undergoes both aan d  f i
The production of unwanted 6 -thiopurine analogues i.e. dinitrophenyl group 
formation via the P-attacking route, does not make thiopurines good candidates for
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cross-linking. In contrast, the property of a-attacking only for t sdnp makes it a 
valuable potential candidate for cross-linking.
6 was stable in aqueous solution for seven days at neutral pH. This property is 
compatible with its use in biological systems where the pH is around neutral. It can 
be stored for much longer time when dry.
To the best of our knowledge the synthesis, characterisation and the stability of 6  has 
not been previously reported and we explored this compound further. The good 
leaving ability of dinitrophenylthio group can be tested by using the very simple 
reagent of mercaptoethanol. It contains two nucleophilic groups a thiol and a 
hydroxyl. Mercaptoethanol is generally used for reducing protein disulfide bonds. It 
is used to cleave intermolecular disulfide bonds to allow the subunits of a protein to 
be separated independently. It is also used to cleave intramolecular disulphide bonds 
to allow denaturation of proteins.
2.5 Reaction of TSDNP with mercaptoethanol
Tsdnp reacted very rapidly with mercaptoethanol at neutral or basic pH to form a new 
compound tentatively assigned as 2-hydroxyethylthiothymidine as shown in Scheme 
9.
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.OH
NH
+  HS' water, room temp
HO.HO.
OHOH
(6) (8)
Scheme 9: conversion of i SDNP to 2-hydroxyethylthiothymidine 
Tsdnp is completely converted to 2-hydroxyethylthiothymidine 
at room temperature.
The reaction was monitored by HPLC (shown in Figure 2.10). The peak of 6 was 
completely converted to two new peaks with UV of 460nm (out of the spectral range 
of Figure 2.10 .(b)) for peak HS-DNP and 308nm for 2-hydroxyethylthiothymidine 8.
2 hydroxyethylthiothymidine
308
273
HS-DNP
TT
220 380260 340300Minutes
nm
Figure 2.10 (a) immediate formation of 2-hydroxyethylthiothymidine from JSDNP (b) UV o f the new 
peaks. Atlantis™ C18 5p (2.1 X  150mm) was used to monitor this reaction 
UV A*naX of 308nm denotes the compound is S-bonded and is likely to be 2- 
hydroxyethylthiothymidine 8. If the compound formed was 0 4-2-
mercaptoethylthymidine (9) (see Scheme 9a) its UV spectrum should be similar to 
that of 0 4-methyl thymidine (10), whose Xrmx is 281nm [107].
O CH<
NH
HO,
OH
(9)
NH
HO.
OH
(10)
Scheme 9a: both the above compounds have similar structure, so should have similar
kind o f UV
The peak was isolated by HPLC and was subjected to mass spectroscopic analysis. 
For further confirmation of its structure a standard compound of 8 was synthesised. 
An alternative method was employed for the synthesis of the standard 8. This 
involves the synthesis of 4-triazolothymidine which would then be treated with 
mercaptoethanol in the presence of triethylamine to form the desired product.
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Synthesis of compound 3 by one pot reaction
2.6 Synthesis of 4-triazolothymidine (5-methyl-4-(l,2,4-triazolyl)-l-(P-2- 
deoxyribofuranosyl) pyrimidin-2(lH)-one, T™)
The procedure in reference [99] was followed for the synthesis of this compound 
which involves the following two steps
Jones’s temporary trimethylsilyl protection procedure was followed to react thymidine 
in THF with chlorotrimethylsilane in the presence of triethylamine which afforded 3’ 
and 5’ protected thymidine[108]. This was followed immediately by triazolation by 
adding phosphorous oxychloride, 1,2,4-liT-triazole and triethylamine as described 
before.
Step -1:
O
Ice bath, Et3N  Me3Si—O 
THF, Me3SiClf 
POCl3
OH
(1) (3)
Scheme 10: Protection and Triazolation were done in the same pot
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Step 2:
The protecting trimethyl silyl groups were removed by treatment with acetic acid in 
methanol solution.
c h 3c o o h , m e o h
Room temp
HO,
OHO
SiMe3
(3) (11)
Scheme 11: deprotection was carried out by adding 1:4 acetic acid 
and methanol stirring at room temperature overnight
The purity of 11 was checked on HPLC and a single peak was obtained (Figure 2.11) 
and used for synthesising the following standards
(a)
iTRI
10 142 6 18 220 260 
Minutes
Figure 2.11 (a) single peak of T™ (b) UV o f T™
(b)
300
nm
340 380
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2.7 Synthesis of standard 2-hydroxyIethyIthiothymidine
11 in methanol was reacted with mercaptoethanol in the presence of triethylamine at 
room temperature to give 8.
v.«NN
HO.
OH
+ HS
(11 )
Scheme 12 Standard 2-hydroxyethylthiothymidine was synthesised by reacting 
with mercaptoethanol at room temperature in presence of triethylamine
Pure 8 was obtained following silica gel column chromatography. The purity of the 
compound was determined by HPLC as shown in figure 2.12.
(a)
2-hydroxyethyIthio
thymidine
10 14 18 22
Minutes
(b)
308.
220 260 340 380300
nm
Figure 2.12 (a) highly pure 2-hydroxyethylthiothymidine was obtained (b) UV
NMR data was obtained which confirms the structure of the compound as shown 
below. The compound was subjected to mass analysis which was similar to that of the 
previously isolated peak of 8.
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*H NMR Data (in DMSO-d6): 1.95 (3H, s, 5-methyl), 2.01-2.28 (2H, m, 2’ and 2"-H),
3.21 (2H, t, a-methylene), 3.60 (4H, m, 5'-H, and p-methylene), 3.83 (1H, dd, 4'-H),
4.21 (1H, m, 3'-H), 5.01 (1H, t, 5'-OH), 5.24 (1H, d, 3'-OH), 6.06 (1H, t, l'-H), 
7.9817 (1H, s, 6-H).
13C NMR (in DMSO-d6) 13.67 (5-CH3), 59.35 (C-5’), 60.81 (P-C of OH), 69.77 (C- 
3’), 85.17 (C -r), 87.73 (C-4’), 110.44 (C-5), 138.60 (C-2), 152.43 (C-6), 176.2 (C-2) 
U V W  308.8;
MS m/z'. 302.88 (M) 186.9 [(M+ H) - sugar) and the mass fragments were obtained 
under electro spray conditions. The observed fragments were M+ 302, M+-H 301 and 
M+H 303.
For further evidence that the synthesised standard and the product formed by the 
reaction of 6 with mercaptoethanol were same, the standard 8 was co-injected along 
with the reaction mixture of 6 and mercaptoethanol on HPLC. The observations were 
as follows:
308.8
HS-DI
HS-DNP 273.2
300
nm
220 260 340 380T
18 22
Minutes
Figure 2.13 (a) HPLC trace o f reaction o f l SDNP with mercaptoethanol (b) UV Xmax o f both peaks
2-hydroxyethylthio
thymidine
2 6 10 14 18 22 220 260 3£)0 340 380
Minutes
Figure 2.13 (c) HPLC trace o f standard 2-hydroxyethylthiothymidine (d) UV l max o f the peak
57
(e)
HS-D
2-hydroxyethylthio
thymidine
I I | I I I | I M | I I I I I I I | I I I | M I | I I I | 111 | I I I | I I I | I I I | I
2 6 10 14 18 22
Minutes
308.8
W5
nm220 260 340 380
Figure 2.13(e): Co -injection o f standard 2-hydroxyethylthiothymidine with reaction mixture o f  
I6™*and mercaptoethanol. Peak o f 2-hydroxyethylthiothymidine was increased with the 
coinjection. So both synthesised standard and the product formed from mercaptoethanol and l 60^
are same.
Possible Reaction Mechanism
NO-
OH
NO-
HS‘
HO. HO.
OH
OH OH
(8)(6)
Scheme 11 thiol attack onTsdnp
The thiol agent is a strong nucleophile and can attack the C-4 of 6 to form 8. The 
sulphur of the formed product was thought to be from mercaptoethanol rather than 
from 4-thiothymidine (5). This could be confirmed by the fact that 5 was not
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observed in this reaction and as discussed earlier 6 undergoes only a-nucleophilic 
attack.
2.7.1 Characteristics of 2-hydroxyethylthiothymidine
The compound was found to be stable in water for an hour as shown in Figure 2.14
(a). However 75% of the compound was hydrolysed after five days as shown in 
Figure 2.14 (c). The new peak has UV at 267nm, which is characteristic of 1. 
Co-injection of standard 1 would confirm the hydrolysed product (see figure 2.14) (g).
(a)l
2 hydroxyethyl 
thiothymidine
i > I j I i ' l  ' [ ' I  I I |  I I  < |  I i I | I I I | I I t j I I I |  I I t |  I
2 6 10 14 18
Minutes
(b) 308.8
273.2
220 260 300 340 380
nm
Figure 2.14 (a) HPLC trace o f compound 8 in water after 1 hour (b) UV Xmax o f compound 8
(C) 267.3
308.8
2 hydroxyethyl 
hiothymidine
250 35014 300
Minutes nm
Figure 2.14 (c) HPLC trace o f compound 8 in water after 5 days (d) UV 2max o f peaks
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2.14 (e) HPLC trace o f standard thymidine (f) UV Xmax of thymidine
(g)
T
2 hydroxyethyl
thiothymidine
k
" l  |  I I I |  I I 1 j i 1 I |  i t  1 |  1 1 I |  i I 1 |  1 I I |  I I I |  I
2 6 10 14 18
Minutes
(h)
267.3
308.8
250 350300
nm
Fig 2.14 (g) HPLC trace o f standard thymidine was injected into 5 day 2-hydroxyethylthiothymidine 
mix. Thymidine peak is increased compare to 2-hydroxyethylthiothymidine. This confirms the extra 
peak formed from the hydrolysis o f compound 8 is thymidine.
So the above experiment confirms that the new peak formed was that of compound 
1. One possible explanation for the formation of compound 1 is the effect of 
neighbouring nucleophile as illustrated in Scheme 12.
Possible reaction mechanism
Scheme 12 : The neighbouring OH group on 2-hydroxyethylthiothymidine attacks the C4<f (5) 
that would eventually lead to theformation <f (1)
Due to the neighbouring effect, the hydroxyl group in the side chain would attack the 
C4 of 5 which might lead to the cyclisation and formation of a temporary five 
membered ring. Due to the presence of excess of water in the surrounding 
environment the oxygen atom of mercaptoethanol is replaced by oxygen of water 
which leads to the formation of 1. This kind of neighbouring effect would be seen 
only if there were other nucleophiles in the molecule. Synthesising a structurally 
similar compound without a neighbouring nucleophile in its structure would provide 
evidence for this mechanism. For this purpose ethanethiol was chosen as the reagent. 
Ethanethiol is similar to mercaptoethanol except for a hydroxyl group. So the final
product formed would have the same structure as that of 8 except for the hydroxyl 
group.
2.8 Synthesis of 4-ethylthiothymidine
4-Ethylthiothymidine (12) was synthesised from 9, by the similar methodology used 
for the synthesis of 8.
N ethanethiol
N
room temp
HO.
OH
HO.
OH
(9) (12)
Scheme 13: Compound (9) in methanol was subjected to react with ethanethiol 
at room temperature in the presence o f triethylamine to form  (12)
The reaction was monitored by HPLC as shown in Figure 2.15 
(a)
rpTR]
__ „ V.... ... f A
12 16 20
246
300250 350nm
Figure 2.15 (a) HPLC trace o f standard triazolothymidine (b) UV l max o fT iTRI
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(C)
iET
.TRI
(d)
274
324.2
250 350300
nm
Figure 2.15 (c) HPLC trace o fT rm converting to ethylthiothymidine with the addition o f ethanethiol.
(d) UV l max o f both peaks
(e)
308.8
250 350300
nm
Figure 2.15 (e) 4-Ethylthiothymidine was isolated and dried. The reaction was left fo r completion 
(figure not shown). It was dissolved in water and injected after five days fig  2.15 (f) UV l max o f T717
Compound 12 is stable compared to 8. This is due to the absence of neighbouring 
nucleophilic hydroxyl group. This not only proves that the presence of hydroxyl 
group in 8 makes it more susceptible to water but that the compound 8 is also S- 
bonded.
So with these studies it could be concluded that, of the different nucleophiles within 
the same molecule the thiol functional group reacts faster with 6. For site specific 
cross-linking, the ideal reagent would be of biological origin and containing a unique 
nucleophile that can displace dinitrophenyl group of 6. Of the natural amino acids
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cysteine is the only amino acid with thiol group in its molecule along with an amino 
group. This unique property of cysteine could be exploited for cross-linking.
2.9 Amino acid cross-linking: Reaction of TSDNP with cysteine
6 reacts with cysteine rapidly in aqueous solution to give a new product which was 
believed to be 4-cysteinylthymidine (13). However, at this stage the exact structure of 
13 was not clear so that it was not explicitly drawn out in Scheme 16
Cysteine
water, cysteine
room temp
HO. HO,
OH OH
(6) (13)
Scheme 16: Compound 6 reacts with cysteine and forms 4-cysteinylthymidine 
at room temperature
The reaction was rapid at room temperature when monitored on HPLC (see Figure 
2.16).
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(a)
HS-DNP
SDNP
Minutes
14 ' ...................18 ' '
(b)
278 (TCYS)
243.8
220 260 300 340 380
Figure 2.16: Cysteine was added to compound 6 and injected immediately at room temperature (a).
UV o f  5 (b). UV of other peaks not shown.
Interestingly the new peak formed has a ^max at 278nm as shown in Figure 2.16 (b), 
similar to the previous observation the S-bonded 8 has UV ^maX at 308nm. Also 5 and 
6 which were S-bonded have UV Im , of more than 300nm as shown in table 1. So, is 
13 S-bonded or N-bonded?
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4S bonded Compounds
4-Thiothymidine 5
rpSDNP ^
UV Xmax (nm)
335
315
2-Hydroxyethylthiothymidine 8 308.8
Ethylthiothymidine 12 308.8
Table 1 representing UV kmax o f various 4S-bonded thymidine derivatives
In an earlier report by Xu [88], a mechanism was proposed for the formation of N- 
bonded, 6-cysteinylpurine-2’-deoxynucleoside from the reaction between 6- 
methylsulphoxypurine-2’-deoxynucleoside and cysteine . The proposed mechanism 
for the formation of the N-bonded compound is shown in scheme 17.
O
\ ^ CH3
N
<N
dR
CHo-CH-COOH
I 1^ NH2
ch2- ch - cooh1 I
s  NH
CH2-CH-COOH 
I I 
SH NH
14
J
Scheme 17 mechanism for transformation of 14 to 17 
(adapted from Xu, Tetrahedron, 54:187-196)
According to the report the 6-methylsulphoxypurine-2’-deoxynucleoside (14) reacts 
with cysteine to form a putative S-bonded 6-cysteinylpurine-2’-deoxynucleoside 
intermediate (15) which was rapidly converted to another intermediate (16). The 
intermediate (16) slowly converts to N-bonded 6-cysteinylpurine-2’-deoxynucleoside 
(17). Purification of the intermediate 15 by HPLC was reported and as was the 
conversion of purified intermediate into the cyclic intermediate 16 and the product 17.
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To support the proposed mechanism it was reported that there was no reaction 
observed between 14 and glycine (simplest amino acid with amino group) under the 
same reaction conditions as with cysteine.
However, in the reaction of 6 with cysteine no intermediates were observed when the 
reaction was monitored on HPLC at room temperature. For comparison the reaction 
of glycine was performed and no products were observed as shown in Figure 2.17 (b). 
This finding is similar to the case of the modified purine analogue i.e., 14, reported by 
Xu [88]. Glycine is the simplest amino acid with an amino and carboxyl group. 
Cysteine and glycine were added separately to 6 in the presence of phosphate buffer 
(pH 6.5) at room temperature and the reaction was monitored by HPLC.
(b)(a) iCYS
HS-DNP
iSDNP
2 6 10
Minutes
14 18
SDNP
'"I i i i | 1 1 ' M ' 1 I 1 ' ' I >''' 1 H" ‘,,‘1 | i' i i | i i i |
2 6 10 14 18
Minutes
2.17 No reaction with glycine was observed (b) as opposed to cysteine (a) where the reaction was
rapid at room temperature
6 was converted immediately to a new peak of 13 (see Figure 2.17 (a)) while new 
peaks were not observed even after leaving for overnight with glycine as seen in 
Figure 2.17 (b). This leads to the conclusion that the thiol of cysteine would attack 
the C4 of 6 first as shown in Scheme 18 and the same pattern as reported by Xu [88] 
might occur.
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OoN
H
H2C---- C— COOH H2C
I 1 is  5^H2 s
‘N
I Very Fast  ^ 7j Very Fast > | | i Very Fast » N
CH-COOH H2C CH-COOH
I 1 INH SH |^|_j
HOs. n  HO HOs. Q HO
OH 0H OH 0H
(6) (18) (19) (20)
Schemel8: Probable mechanism for the formation of N-bonded 4-cysteinylthymidine
To examine the above hypothesised mechanism another set of experiments were 
carried out where slightly less than equimolar concentration of cysteine was added to 
6 as mentioned earlier. The reaction was monitored by HPLC and the temperature of 
the reaction was maintained at 5°C through out the reaction. This setting up of 
temperature to 5°C was made possible by using Waters™ 2690 HPLC instrument. 
The observations were as follows 
(a)
SDNP
314.7
220 260 340 380
Figure 2.18: 6  was already at 5°C for 20 min (a) and the UV (b)
To the above pre-cooled 6, cysteine was added and injected immediately. The 
following pattern was observed.
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278(3) 310.0(2)
269.7
243.I
/278{ ‘
220 260 300 340 380
(a)
iSDNP
CYS
aJ
22
Figure 2.19 (a) 6  was immediately converted to new peaks on addition o f cysteine, (b) UV o f new 
peaks- designated as 3,4,5. (CYS for cysteine)
Peak 2 in Figure 2.19 (a) has Amax at 310nm. This would appear to be the peak of S4- 
cysteinylthymidine 18 based on the data in Table 1 showing that all S4-bonded 
thymidine derivatives show a maximum UV absorption above 300 nm. This was also 
reported in various literature references [76, 109]. S4-bonded 4-thio-5- 
bromodeoxyuridine has Amax of 335nm and 4-thiothymidine was shown to have Amax 
of 330nm. Other known S4-bonded derivatives of thymidine such as 4- 
glutathionylthiothymidine (see below) have UV AmaX around 310 nm as shown in 
Figure 2.20. Peaks 2, 3 and 4 were not isolated.
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308 (a)
Figure 2.20: UV o fS  -thymidine derivatives. Peak (a) 2-hydroxyethylthiothymidine, peak (b) 4- 
cysteinylthymidine and (c) 4- Glutathionylthymidine. All the peaks have similar UV patterns
The S4-bonded compounds such as glutathionylthiothymidine, 2- 
hydroxyethylthiothymidine and S4-cysteinylthymidine have structural similarity as 
shown below and have the same UV patterns as shown in figure 2.21.
H2C CH-COOH
I I
S NH?
NH
HO,
OH
COO
O
NH
HO
OH
S4-cysteinyIthymidine S -glutathionylthymidine fi-hydroxyethylthiothymidine
Figure 2.21 Chemical structure of S4-bonded thymidine compounds
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Thus peak 2 can be tentatively assigned as S -cysteinylthymidine 18.
Peak 3 and 4 have the same UV maximum absorption at 278nm. This is characteristic 
feature of N4-bonded thymidine derivatives. 21 has maximum UV absorption at 278 
nm. All N4-bonded thymidine derivatives have UV around 280 as shown in Figure 
2.23. So it is reasonable to assume that peak 3 and 4 are N4-bonded 
cysteinylthymidine derivatives.
•01.5
278
278
350250 300220 260 300 360
Figure 2.23 (a) UV of N4-cysteinylthymidine (b) UV o f 5-methylcytidine
5-Methyl cytidine (21) is structurally similar to N4-cysteinylthymidine (20) as shown 
in Figure 2.22.
COOH
HO.
OH
20
Figure 2.22 Structure o f N4-bonded thymidine derivatives
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When the reaction was monitored after an hour peak 2 disappeared completely and 
peak 3 remained as the major peak as shown in Figure 2.24. At this stage the starting 
material (t sdnp) peak also disappeared.
3
6 7
4 5
I  Ik
2 6 10 14 18 22
Figure 2.24: the reaction was monitored after an hour.
The reaction was maintained at 5°C
Peak 5 was assigned as compound 7 (i.e. the leaving group) which has UV at 
406nm. Peak 6 was assigned as cysteine which was confirmed by injecting a standard 
of cysteine. When the reaction was left for overnight and monitored peak 3 was 
slowly converted to peak 4 which has similar kind of UV.
2 6 10 14 18 22
Figure 2.25: after overnight peak 3 was converted to peak 4.
The reaction temperature was still maintained at 5°C
Peak 7 has increased in size after leaving the reaction mixture for overnight with UV 
^max of 278nm which is again characteristic of N4-bonded thymidine derivatives as 
discussed earlier. This peak was not observed on immediate injection of the reaction
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mixture and developed into another major peak after leaving the reaction overnight. 
The retention time of this peak was at 2.5 minutes, implying, a highly polar 
compound, as highly polar compounds elute first on reversed phase column. This 
peak was observed only in the presence of free cysteine in the reaction mixture. 
There data were consistent with peak being Tcys—^cys (4-cystinylthymidine 22 as shown 
in figure 2.24) as excess cysteine in the reaction mixture is likely to slowly form a 
disulphide link with N4-cysteinylthymidine.
In the absence of excess cysteine peak 7 (22) was not observed as shown in figure
HOOC HC CH2 HoC— CH—COOH
I .  I I II I  I I
K|H2 S ----------S NH
OH
22
Figure 2.26 Structure o f 4-cystinylthymidine (J£ys'cys)
2.27.
4
2 6 10 14 18
Figure 2.27: N4-cysteinylthymidine isolated peak
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Peak 4 has UV absorption maximum at 278 which is exactly similar to that of peak 3 
suggesting that it was a similar type of compound. The retention time was slightly 
later than that of peak 3 which suggested that it was less polar. Taking into 
consideration the fact that free thiol groups are susceptible to oxidation and usually 
generate disulfides, the free thiol group of N4-cysteinylthymidine might form 
disulphide bridges among themselves to form a dimer (Tcys'cysT) 23. Further support 
for this proposal came from the fact that peak 3 was completely converted to peak 4 
after four days as shown in the Figure 2.28.
2 1810 14 226
Figure 2.28: after 4days peak 3 was totally converted to peak 4
To confirm that peak was that of 23 a separate set of experiments were performed to 
see if the disulphide bonds could be broken to regenerate peak 3 .
2.9.1 Reducing disulfide bonds
Dithiothreitol (DTT), also known as Cleland’s reagent, contains two thiol groups and 
is widely used in biochemical studies for reducing disulphide bonds of proteins.
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(a)
c h 2 — — S H
C H --------- — O H
C H --------- --------O H
1OJX
—
o
— S H
( b )  H O O C — C H - C H 2  C H 2 ' C H - C O O H
d Rd R
Figure 2.29 (a) l,4-Dithiothreitol,(l,4-dimercapto-2,3-butanediol) 
(b) rf-cysteinylthymidine dimer ( ]cys'cysT)
If the proposed structure for peak 4 is correct (as figure 2.29 (b)) then it should be 
reduced to peak 3 on addition of DTT and the new peak should be eluted at earlier 
time without any change in the UV Xmax. For this purpose an authentic 23 standard 
was synthesised using 11.
Compound 11 in water reacts with cysteine in the presence of triethylamine at room 
temperature and forms 20. 20 subsequently dimerises, forming disulphide linkages 
among themselves to form compound 23.
N
N
d R
11
O H
C -
O
H H  O H
c  c h 2 H 2 C  C
‘N ^ O
d R
20
+
N H  S H  S H  N H  o  H O O C - C H - C H 2  C H 2 - C H - C O O H  
' ‘ N H  S ------------ S  N H
Scheme 19: 11 in water reacts with cysteine in the presence o f triethylamine at room temperature 
to form  20. the formed 20 would form disulphide bonds to form  23
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When the reaction was monitored by HPLC, interestingly a peak with UV at 
310nm was first observed as shown in figure 2.30 and then disappeared immediately.
300250 350182 6 10 14
Minutes nm
Figure 2.30 (a) Reaction o fT rm& cysteine (peak 2 appeared for a very short time at 5°C) (b) UV
1-max o f the peaks
The synthesised 20 was purified by silica gel column chromatography and upon 
analysing by HPLC shows a single peak as shown in figure 2.28 (a), which has UV 
A-max at 278nm as shown in figure 2.31 (b).
(a)
2 6 10 14 18 22
(b)
(^50220 260 340 380
Figure 2.31 (a) 4-cysteinylthymidine (b) UV o f 4-cysteinylthymidine
The compound formed was presumed to be 23 rather than 20. If this is true then the 
disulphide bonds can be broken by addition of a reagent such as DTT. This reagent is
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used in biology laboratories to break the disulphide bonds between proteins. 23 was 
subjected to react with DTT in water and the reaction was monitored at different time 
intervals on HPLC.
Reaction of DTT with Peak 4 (Tcys cysT)
(a)7 rjicys-cysrji ^
279
260 300 340 380220
Figure2.32 (a) In the above profile DTT was not added yet. 
(b) UV of peak 4 (T ys'cys)
(C)
2 106 14 18 22
(d)
278
242.6
220 300 340 380260
Figure 2.32 (c) DTT was added and injected into HPLC (lhour). Formation o f  
new peak was observed, (d) UV Xmax o f peak 3& 4.
i  i i i i i i |  i < < I u  i 1 1  u  |  * i .  |  i 1 1  |  i n  [ T i ' i ' i  r i  i |  i i i | i i i |  i I
27|
278
220 260 300 340 3802 6 10 14 18 22
Figure 2.32 (e) after two hours the reaction mixture was again injected into HPLC.
New peak (3) is taller than old peak, (f) UV Xmax of peak 3& 4.
11
2 6 10 14 18 22
(h)
220 260 300 340 380
Figure 2.32 (g) Complete conversion of peak 4 to peak 3 was observed. So peak 4 can be confirmed 
as T*ys'cysT. represents 7 CVS CVS7 ' (N4-cysteinylthymidine dimer) —  repr esents 7*ys (N4-
cysteinylthymidine)
So Peak 4 was converted to a new peak which had the same retention time and UV as 
that of peak 3 under the same conditions. This proves that peak 4 is formed from 3 
and is dimer of N4-cysteinylthymidine (xcys'cysT).
Possible Reaction Mechanism:
C H o-C H -C O O H  C H 2-C H -C O O H
I I I Is NH SH NHSH HOOC
C H o-C H -C O O H
C H o-C H -C O O H
I I
SH NH
H 'C O O H
d R  d R
Reaction <f DTT with T ^ '^ T
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Thiol groups are susceptible to be oxidised and usually generate disulfides. In this 
case the free thiol groups of individual molecules of 20 gets oxidised and generates 
disulfide links among themselves (formation of dimer x cys'cysT). Tcys in the presence 
of free cysteine forms a disulphide link and forms 4-cystinylthymidine (Tcys‘cys) peak 
7.
The entire reaction between t sdnp and cysteine can be represented schematically (see 
scheme 21).
19
no2
H2C— CH—COOH
H2C CH-COOH
N02
NH
Cysteine NH
dR (18) dR 
Very Fast,N02
HS NO;
(7)
(19)
H2C— CH-COOH
I I
SH NH
H2C—CH-COOH
I I
SH NH2 
cysteine
HOOC— CH-CH2 H2C
I I 1NH S------- S
•CH-COOH HOOC— HC— CH2 H2C— CH-COOH
I 1 1 i
nh2s --------s  NH
Scheme 2 1 : Representation o f entire reaction between 1 ^ °^  and Cysteine.
With all the above evidence it could be concluded that compound 6 reacts with thiol 
containing cysteine and forms S4-cysteinylthymidine which rapidly rearranges intra 
molecularly to form N4-cysteinylthymidine. The free thiol group in the N4- 
cysteinylthymidine molecules reacts with either free cysteine to form 
cystinylthymidine or dimerises.
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2.10 Peptide Cross-linking: Reactions with glutathione
Glutathione is widely distributed in animal tissues, plants and micro organisms [110]. 
It is the most prevalent thiol in the cells and the most abundant low molecular weight 
peptide [111]. In the cytosol of the cells glutathione reduces disulphide bonds within 
proteins and protects the cells from reactive oxygen species (ROS). It is an important 
component of the system that uses reduced pyrimidine nucleotide to provide the cell 
with its reducing properties, which promotes intracellular formation of cysteine from 
cystine and thiol forms of proteins. Other important functions of GSH in vivo include 
catalysis, metabolism, and transport. It also participates in the reactions involving 
synthesis of proteins and nucleic acids. The intracellular level of glutathione is much 
greater than that of cysteine and serves as a storage for cysteine moieties [111, 112]. 
Chemically glutathione is a tripeptide consisting of glutamate-cysteine-glycine and is 
usually denoted by GSH for reduced form and GSSG for oxidised form where two 
glutathione peptides are joined by a disulphide bond. GSH has two characteristic 
structural features of y-glutamate linkage and -SH which are responsible for its 
intracellular stability and functions [113]. The thiol of glutathione moiety could be 
useful for site specific cross-linking similar to that of cysteine as seen earlier.
Glutathione reacts with t sdnp and forms 4-glutathionylthymidine (TGlu) as shown in 
Scheme 22.
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Glu
NO-
glutathione, water
room temp
HO. HO.
OH OH
(9) (24)
Scheme 22: in water reacts with glutathione to form 4-glutathionylthymidine.
The reaction was slow when compared to cysteine and mercaptoethanol. The reaction 
was monitored by HPLC as shown in Figure 2.33
(a)
iSDNP
HS-DNP(2)
10 18 22fd i 14 340 380220 260 300
Minutes
Figure 2.33: (a) glutathione reacts with TSDNP in the presence o f water to form I 0111 
(b) UV Xmax o f the individual peaks. Xmax = 310 for 1clu.
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.SDNP reacts with glutathione in water and forms two new peaks as shown in Figure
2.33. t sdnp was completely converted to peaks 1 and 2 in 24 hours as shown in the 
following figure 2.33 (c).
(c)
10 14 18 22""
Minutes
(d)
270.9
250 350
nm
Peak 2 has UV A™aX of 406nm and is characterised as HS-DNP as previously. Peak 1 
has UV A-max of 310nm. As previously shown in Table 1, S4-thymidine derivatives 
have A,max at 310nm. The thiol group of cysteine moiety in glutathione would attack 
the C4 of Tsdnp. Interestingly the product formed with glutathione is S-bonded and 
remains S-bonded in solution at room temperature. Unlike 4-cysteinylthymidine an 
N-bonded product was not observed even after a week in the solution. Even though 
glutathione contains several functional groups, only the thiol of the cysteine moiety 
attacks the C-4 position of t sdnp to form TGlu. This could be explained by the fact 
that the adjacent amino group in glutathione is in a peptide amide form and no longer 
free to attack the C-4 position after the formation of S-bonded product. A standard 
(24) was synthesised for further evidence.
2.11 Synthesis of standard 4-glutathionylthymidine
The same methodology for synthesising 4-cysteinylthymidine and 2- 
hydroxyethylthiothymidine was employed for synthesising the standard for 4- 
glutathionylthymidine. This involves the 4-triazolothymidine as the starting material
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which reacts with glutathione in the presence of triethylamine to form 4-glutathionyl 
thymidine 24.
y-glutamate— N— C— C-Alanine 
CH?
glutathione 
room temp
HO. HO.
OH OH
W  (24)
Scheme 23:4-triazolothymidine in water reacts with glutathione in the presence 
of triethylamine at room temperature to form 4-glutathionylthymidine
The purity of the synthesised compound was checked on HPLC which shows a single 
peak.
(a) -GLU
2 6 10
Minutes
14 18 250 350
Figure 2.34: (a) Synthesised 4-glutathionylthymidine shows a single peak implying high degree o f
purity, (b) UV o f 1°™
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The compound was characterised and confirmed by the data from high resolution 
mass spectrometry m/z 532.1705 ([M++l]), which was then co-injected with the 
reaction mixture of TSDNP and glutathione (see figure 2.34).
(c)
(a) -SDNP
2 6 10 14 18 22
Minutes
I i 1 ' \ ' * » I i * U  ' i » I » 1 ' I '
10 14 18 22
Minutes
Minutes
(b)
HS-DNR
-SDNP
220 260 300 340 380
nm
(d)
270.9
250 350
nm
(e)
-SDNP
-GLU
HS-DNP
L - A
2 6 10 14 18 22
iGLU HS-DNP
-SDNP
T300r
nm
220 260 340 380
Figure 2.35 (a) Reaction o f I SDNP with glutathione, (c) Standard TGLV. (e) Co-injection o f (a) and (c) 
shows increase in the peak height ofT GLV in relation to the adjacent peaks.
This co-injection experiment (Figure 2.35) proves that the product formed from the 
reaction between t sdnp and glutathione was t glu.
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In summary, from the results so far it could be concluded that 4-thiothymidine can be 
activated by various reagents such as FDNB/C1DNB to form a good leaving group -  
4-S-(2,4-dinitrophenyl) - which can be specifically substituted by various thio- 
nucleophiles. The thio-nucleophiles could be either chemical reagents such as 
mercaptoethanol, ethanethiol or unique biological molecules such as cysteine and 
glutathione.
These results and methodology could be extended to various other thiopurine or 
thiopyrimidine analogues and also to the DNA containing thionucleosides.
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CHAPTER 3
Synthesis and Reactions of 4-Thio-5-bromodeoxyuridine
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3 Synthesis and reactions of 4-thio-5-bromodeoxyuridine
3.1 Introduction
Bromodeoxyuridine (BrdU) is a thymidine analogue with a bromine substituent at 
position 5. BrdU can be incorporated into DNA during synthesis and is a very useful 
biochemical tool that has also attracted interest as a chemotherapeutic agent in the 
treatment of prostrate cancer. Monoclonal antibodies that recognise BrdU are used to 
identify cells that have incorporated BrdU and are used to detect and measure cell 
proliferation [76]. BrdU is a potent sensitizer Cancerous cells when compared to 5- 
fluorouracil (5-FU) in the treatment of some forms of cancers.
In the quest to develop new novel synthetic drugs against cancer, 4-thio-5-bromo-2’- 
deoxyuridine (S4-BrdU) was recently synthesised in our group as a reagent for UVA 
induced cell killing [76]. The advantage of S4-BrdU over 4-thiothymidine was that it 
could be recognised by the available monoclonal antibodies used against DNA 
containing BrdU [76]. The cross-recognition was ascribed to the presence of the large 
bromine atom in S4-BrdU as a distinctive structural feature compared to the relatively 
small effect of substituting sulphur for oxygen.
An important property similar to 4-thiothymidine was that S4-BrdU was not toxic to 
cells over a range of concentrations [76]. The very promising results for cross-linking 
with 4-thiothymidine reported in the previous chapter prompted us to explore the 
potential of S4-BrdU for site-specific cross-linking. Xu et al\16\ first reported the 
synthesis of S4-BrdU and its key properties. Synthesis of S4-BrdU is similar to that of 
4-thiothymidine and involves the 4 steps as shown in Scheme 3.1 (a) to 3.1 (d).
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3.2 Synthesis of S4-BrdU 
Step-1
The first step involves the protection of 3’ and 5’ OH groups of sugar with 
trimethylsily groups as shown in Scheme 3.1 (a). 5-Bromodeoxyuridine (25) was 
suspended in THF and reacted with trimethyl chlorosilane in the presence of triethyl 
amine to give 3 \  5v-0-bis-(trimethylsilyl)-5-bromodeoxyuridine (26).
O O
SiMe^EtfN
(25) (26)
5-bromodeoxyuridine 3',5'-0-bis-(trimethylSilyI).5-bromo
deoxyridme.
Scheme 3.1 (a) Protection if  3' and 5' OH of thymidine
Step-2
26 in acetonitrile was treated with 1,2,4-1H triazole in the presence of triethylamine 
and phosphorous oxychloride to give 4-triazolo-3\5v-0-bis-(trimethylsilyl)-5- 
bromodeoxyuridine as shown in Scheme 3.1 (b).
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Br
O
Et3N, Triazole;POCl3
Br
'O
RO
Me3SiO
OR
(26) OSiMe3
(27)
3',5'-0-bis-(trimethylsilyl)-5-bromo 4-triazolo-3f,5f-0-bis-(trimethyIsiIyl)-5- 
deoxyridine. bromodeoxyridine.
Scheme 3.1(b) Triazolation o f C4 o f thymidine
Phosphorous oxychloride and l,2,4-(lH)-triazole are added to 26 in acetonitrile. 
Triethlylamine is added in 2:1 molecular ration in the beginning of the reaction and is 
not only used to neutralise the formed HC1 but also abstract a proton from 1-N of 
triazole.
Step-3
27 in acetonitrile was treated with thiolacetic acid to give 4-thio-3\5v-0-bis- 
(trimethylsilyl)-5-bromodeoxyuridine.
(27)
4-triazolo-3’,5'-0-bis-(trimethyIsiIyl)-5- 4-thio-3',5'-0-bis-(trimethylsiIyl) 
bromodeoxyridine. -5-bromodeoxyridine.
Scheme 3.1 (c) thiol group formation at C4
c h 3c n , c h 3c o s h
room temp
(28)OR
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Step-4
The trimethylsilyl groups hydrolyse in the presence of acid and form 4-thio-5- 
bromodeoxyruidine.
Br
y n  c h 3c o o h , m e o h
Ice bath
NH
RO. HO,
OR OH
4-thio-3’,5f-0-bis-(trimethylsilyl)
-5-bromodeoxyridine. 4-thio-5-bromodeoxyuridine
Scheme 3.1 (d) formation of 4-thio-5-bromodeoxyuridine 
3.3 Modification of S4-BrdU
A similar protocol to 4-thiothymidine was followed for the modification of 4-thio-5- 
bromodeoxyuridine (S4-BrdU). As shown earlier for 4-thiothymidine, the chosen 
reagent for the activation of S4-BrdU was 2,4-dinitrofiuorobenzene (FDNB).
FDNB reacts with 29 in the presence of phosphate buffer pH 9.5 to form S4-2,4 
dinitrophenyl-5-bromodeoxyuridine (S4-BrdUDNP) as shown in Scheme 3.2.
NO-
NO
NH NO- NH
+ HF
*0 RT; pH  9.5
HO. HO.
OH OH
(30)
Scheme 3.2: Formation o f S4-BrdUDNP from the reaction o f S4-BrdU and FDNB
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The reaction was monitored on HPLC as shown in figure 3.1 
(a)
FDNB
S -BrdU
(b)
133.8 (2)
250 350 450
Minutes
nm
Figure 3.1: (a) Reaction o f S4-BrdU with FDNB in phosphate buffer (b) UV Lnax
Two new peaks were observed. Peak 1 has retention time at 2.5 minutes with a UV 
A-max 299.3nm and peak 2 was eluted at 29 minutes with a Xmax of 333.8nm.
A blank was run to identify the above observed peaks.
(a)
FDNlJ
| ' v  | 'i i 11 11 | t | | | | i | | | | | | j | | j |
5 10 15 20 25 30
Minutes
250 350 450
Figure 3.2 (a) FDNB and phosphate (pH 8.5). (b) UV Xmax o f the peaks
When the phosphate buffer (pH 9.5) was added to the reagent FDNB a new peak (1) 
was observed. This new peak has the same retention time and UV as peak (1) in 
Figure 3.1 (a) of the reaction mixture. This confirms that the peak 1 in figures 3.1 (a) 
and 3.2 (a) are the same.
Blank reaction with S4-BrdU and phosphate buffer was monitored by HPLC
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(b)
25U 450
i t  i  I  |  i  i  i  i  |  i  i  i  i  |  i i  i  i  |  i  i r - T - | "  i  i " i  t " | 1
5 10 15 20 25 30
Minutes
Figure 3.3 (a) S -BrdU was added to phosphate buffer at pH  9.5 and monitored on HPLC (b)
LJV Xmax o f peak o f S4-BrdU
As monitored above on the HPLC new peaks were not observed. So peak 1 was 
formed from the reagent FDNB and not significant to study further. Peak 2 has 
UV ^max at 333.8nm which is typical for S4-BrdUDNP.
The peak 2 of S4-2,4-BrdUDNP was isolated as shown in the figure 3.4 (a) and the 
UV Xmax was measured as in 3.4 (b). This isolated peak was used for further 
reactions with thiols.
(a) (b) i
331.4
30 250 300 350
nm
450
Minutes
Figure 3.4 (a) Isolated peak ofS 4-BrdUDNP (b) Xmax o f S4-BrdUiD N P
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3.4 Reaction of S4-BrdUDNP with various nucleophiles:
30 in water for 7 days hydrolyse and form 25 and 7 as shown in scheme 3.5.
NO;
NH
dR dR
NOc
HS N 0 2 
(7)
(3°) (25)
Scheme 3.5 Hydrolysis o fS 4-BrdUDNP
Only compound 25 was observed on hydrolysis. Compound 29 was not observed. 
This is consistent with the data observed for compound 6. So it could be 
concluded that dinitrothiopyrimidines undergo only nucleophilic attack at C-4 (a- 
attacking route) and not C-l of the aromatic ring (P-attacking route) as shown in 
scheme 3.6. This is different for dinitrothiopurines as reported by Xu [94] as 
shown in scheme 8.
S N 02
Scheme 3.6 attacking route o f S4-BrdUmP
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Compound 30 was subjected to react with various thionucleophiles such as sodium 
sulphide and mercaptoethanol to confirm the mechanism in scheme 3.6
3.5 Reaction of S4-2,4-BrdUDNP with sodium sulphide:
30 was treated with sodium sulphide and injected into HPLC. The observations were 
as follows.
(a) ]
S4-BfrdU(1)
rlS-DNP(2)
S4-2,4-
dnpBrdU(3)
10 155 20 25 30
Minutes
(b)
-1(1)
1(2)
329(3)
250 300 350 400 450
Figure 3.4: (a) reaction o f S4-2,4BrdUDNP with Na2S (b) UV of the peaks
Sodium sulphide reacts with 30 and forms 29 and 7. In this reaction 25 was not 
observed in the above profile. The sulphur in 29 is formed from sodium sulphide. 
The sulphur atom from 30 transferred to compound 7. Standards of compound 25 and 
compound 29 were injected to compare the retention times.
(a)
5-BrdU
" 1  i  i  j i  i  i  i  j I i  i  i  j  i i  i  i  j  i  i  i  i j i  i  T
5 10 15 20 25 30
Minute
\9.2
250 300 350 400 450
Figure 3.5: standard o f 5-BrdU (b) UV o f 5-BrdU
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(a) S -BrdU (b):
300 350 400 4505 10 ,15 , 20 25 30Minutes
Figure 3.6: standard o fS 4-BrdU (b) UV of S4-BrdU
The peaks from the reaction mixture in Figure 3.4a and the standard (S4-BrdU) have 
similar retention times (13 minutes). So a co-injection was performed to confirm the 
product.
(a)
S4-BrdU
HS-DNP
Minutes
16.1
413.7
250 300 350 400 450
Figure 3.7: Co-injection o f S4-BrdU with the reaction mixture o f S4-BrdUDNP with Na2S
So the co-injection from Figure 3.7 confirms that the product formed from the 
reaction of 30 with sodium sulphide was that of 29. Since 5-BrdU peak was not 
observed, it could be confirmed that like the compound 6, compound 30 also 
undergoes thiol substitution as shown in Scheme 3.5.
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(30)
NO-
NO.
NH
NH
Room temp
HO, HO.
OH OH
NOc
HS N02
(7)
(29)
Scheme 3.5: Sodium sulfide reacts with S4-BrdUDNP to form S4-BrdU
3.6 Reaction of S4-DNPBrdU with various thiols:
3.6 (a) Reaction with mercaptoethanol
To show that compound 30 could be used as a good intermediate for cross-linking it 
was first treated with mercaptoethanol at room temperature and the reaction was 
followed by HPLC. The observations were as follows:
(b) i(a)
331.4
250 300 350 400 450nmMinutes
Figure 3.8: S4-2,4-BrdUDNP (b) U V lmax of S4-2,4-BrdUlD N P
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(b)
p-hyd roxyethyl borlomodeoxy uridi ne
17.1
[S-DNP
30 250 300 330 400 450Minutes
Figure 3.9 reaction o f S4-2,4BrdUDNP with mercaptoethanol 
Compound 30 was first injected into the HPLC on its own as shown in figure 3.8.
Then an equivalent amount of meracaptoethanol was added to the same vial and
immediately injected into HPLC. The compound 30 has completely changed to a
major new peak with UV ?wx of 317nm and minor peak at 412.5nm as shown in
figure 3.9 . This new peak can be tentatively assigned as the compound 31. As per
our earlier discussion the for 8 was 309nm and all the S4-bonded thymidine
compounds would have UV A,max of more than 300nm. So compound 30 can react
with thionucleophile such as mercaptoethanol and form 2-
hydroxyethylthiobromodeoxyuridine (31) and dinitrothiophenol (7) as shown in
Scheme 3.6.
NO-
.OH
NO;
NO-
mercaptoethanoj.
room temp
HS NO;
HO. HO.
OH OH
(30)
Scheme 3.6: Mercaptoethanol reacts with S4-BrdUDNP to form 2-hydroxyethylthiobromodeoxyuridine
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3.7 Reaction of S4-BrdUDNP with cysteine
30 was treated with cysteine at room temperature and the reaction was monitored on 
HPLC. The observations were as follows:
(b)
\0.9 (1)
■•5(4)
i-6(3)
30 400250 300 450
Minutes
Figure 3.10: Immediate injection o f reaction o f 30 with cysteine
Peak 1 can be assigned as the reagent cysteine. Peak 2 has UV 'kimx of 319.5nm. As 
discussed earlier all the S4-bonded pyrimidines have the UV Xmax at more than 300nm. 
So, peak 2 can be tentatively assigned as S4-cysteinyl-5-bromodeoxyuridine. Peak 3 
has UV Xmax at 288.6nm which is characteristic of N4-bonded pyrimidine derivatives. 
So peak 3 can be tentatively assigned as N4-cysteinyl-5-bromodeoxyuridine. This 
peak should increase over the time if compound 30 undergoes similar substitution 
with cysteine. So the same reaction mixture was injected into HPLC and monitored 
after 4-hours and the observations were as follows:
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(b)
411.3(4)270.9(1)
318.3 (2)
250 300 350 400 450
(a)
10 15 205 25 30
Minutes nm
Figure 3.11: after 4 hours peak 2was converted to peak 3 
(Conversion o f S-bonded 4-cysteinyl-BrdU to N-bondedproduct)
As expected peak 2 was almost completely converted into peak 3 after 4hours (as seen 
in figure 3.11) and this would support our proposed mechanism that first the thiol of 
cysteine would attack followed by ring rearrangement to a stable N-bonded 4- 
cysteinyl-5-bromodeoxyuridine.
We propose the reaction mechanism as similar to that of previously described for 
formation of 20. The excerpts of the reaction mechanism for the formation of 4- 
cysteinyl-5-bromodeoxyuridine were, first the thiol group of cysteine molecule would 
attack at C-4 position of 30 and forms an S4-cysteinyl-5-bromodeoxyurine which 
would then be attacked by the adjacent amino group in the same cysteine molecule to 
form an N4-cysteinyl-5-bromodeoxyuridine.
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ch2- c h - cooh
NH-
-V Cysteine
HO.
HO.
OH
OH(30) (32)
CH2-C H — COOH
CH2—CH— COOH
NH
HO.HO.
OHOH
NH
(34) (33)
Scheme 3.7 Conversion o f S4-BrdUDNP to N4-cysteinyl-5-BrdU
3.8 Reaction with glutathione
Glutathione reacts with S4-DNPBrdU to form 4-glutathionyl-5-bromodeoxyuridine. 
The reaction was very slow when compared to that of other thionucleophiles such as 
sodium sulphide, mercaptoethanol and cysteine. This could be due to the steric bulk 
of the glutathione molecule making the thiol in glutathione less reactive.
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NO-
NO- Glu
glutathione 
room temp
HO.HO.
OH (35)OH (30)
Scheme3.8: S4-BrdUDNP in water reacts with glutathione 
to form 4-glutathionyl-5-bromodeoxyuridine
Glutathione was added to 30 in water and injected into HPLC as shown in figure 3.12. 
Two new peaks were observed. Peak 1 is that of compound 30, peak 2 has UV ^max at 
319nm. Peak 3 has UV Xmax at 406.5nm which is consistent with that of 
dinitrobenzenethiol (7) as previously discussed.
(a)
BrdU
HS-DNP
1510 20 25 305
Minutes
(b)
319.5(2)
1^(1)
450250 300 350 400
Figure 3.12 (a) reaction o f S4-2,4-dnpBrdU with glutathione the reaction is slow when compared 
with the reaction with formerly used thiol reagents under the same conditions(b) UV l max o f the
peaks
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The reaction was monitored at different time intervals (data not shown) and when the 
reaction was left overnight the starting material (S4-DNPBrdU) was completely 
converted to new peak of 4-glutathionylbromodeoxyuridine (BrdUGlu).
BrdU
318.3(2)
276.8
406.5 (3)HS-DNP (3)
5 10 15 :
Minutes
20 25 30 250 400300 350 450
Figure 3.13: (a) the same reaction mixtures from figure 3.12 were re-injected after leaving for  
overnight for the reaction to complete (starting material completely converted to product) (b) UV
)-max of the peaks were shown
3.9 Conclusions
S4-DNPBrdU undergoes the same kind of nucleophilic substitution as that of S4- 
DNPthiothyrriidine i.e., a-nucleophilic substitution. The products formed have a 
similar UV pattern to that of products from S4-DNPthiothymidine but with a slightly 
longer wavelength (about lOnm longer).
The above results allow us to conclude that the thiol group of S4-BrdU could be 
specifically modified by a suitable reagent such as FDNB and the intermediate could 
be used for cross-linking with various thiol nucleophiles. Using S4-BrdU could be an 
advantage over 4-thiothymidine because it can be recognised by monoclonal 
antibodies. This might help to identify the cross-link in cellular DNA.
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CHAPTER 4 
DNA STUDIES
4 DNA studies
Oligonucleotides containing modified bases are used in a variety of areas such as 
studies of carcinogenic compounds, investigations on DNA-RNA activity and DNA- 
protein interactions [114]. In the context of this thesis the modified nucleosides can be 
considered as ‘convertible’ nucleosides [115] and the process of substituting them 
with the desired groups has been termed as ‘post synthetic' substitution’ [103].
One approach to site-specific chemical cross-linking of DNA was initially explored 
by Xu [88] in which a novel method to chemically crosslink cysteine or peptides 
containing cysteine with reactive DNA containing 6-methylsulphoxypurine in a site 
specific manner was described [88]. Some difficulties were encountered in producing 
‘clean’ products with thiopurines. The very promising cross-linking results reported 
in the previous chapters with nucleosides encouraged us to explore the use of 
thiopyrimidines for oligomer studies. The first step was to . synthesise an oligomer 
incorporating 4-thiothymidine.
4.1 Synthesis of oligonucleotides:
Chemical synthesis of DNA was started in 1950s in Sir Alexander Todd's lab in 
Cambridge. In the late 1960s Khorana and his co-workers developed phosphodiester 
chemistry for the synthesis of oligomers. Purification of oligomers was difficult with 
this method. In mid 1980s the Merrifield solid-phase synthesis method was adapted 
for the synthesis of DNA. With this method the purification of intermediates was 
eliminated. The solid phase method was then combined with fast reacting 
phosphoramidite approach developed by Caruthers, in which each cycle is shortened 
to a few minutes. Automated DNA synthesis with phosphoramidite chemistry is now 
the method of choice and its use has shaped modem face of biotechnology. The
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chemistry of synthesising short sequences of DNA has reached an advanced stage. 
Numerous synthetic oligomers are produced by DNA synthesisers and used as probes 
for interaction with proteins, as primers for polymerase chain reaction (PCR) and for 
various other studies. However the synthesis of base-modified DNA remains 
challenging and various groups are seeking to develop better methods [116].
4.2 Synthetic Chemistry of Unmodified DNA:
The structures and chemistry of deoxynucleoside phosphoramidite monomers are 
shown in Figure 4.1. As discussed earlier for DNA (in Chapter-1), the monomers are 
also made of three parts: base, sugar and phosphoramidite. These monomers are 
commercially available and directly employed for the synthesis of DNA by automated 
DNA synthesisers [116].
Phosphoramidite Protected bases
dR
Adenine Guanine
NH- Ri O
dR
Cytosine
dR
Thymine
Protecting groups DM-
OMe
Figure 4.1: Phosphoramadite monomers o f Standard Bases
(figure adapted from reference [116] ).
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(a) Bases
The standard bases A, G and C have amino group that requires protection. Acyl 
groups are used for this purpose. A benzoyl group is generally used for the protection 
of A and C and isobutyryl group for G, depending on their removal by the 
deprotecting agent which is usually ammonia. These protecting groups remain on the 
bases during the synthesis and are removed after the synthesis. Thymine does not 
need to be protected since it does not have free amino group on it.
(b) Sugar:
The 5'-hydroxyl group of deoxyribose is protected with the dimethoxytrityl group 
(DMT), which is acid-labile and readily removed during the synthesis of DNA to 
provide free hydroxyl group for elongation. When DMT is released an orange colour 
is observed which can be used for monitoring the coupling yields.
(c) Phosphoramidite:
This amidite, in the presence of tetrazole is very reactive towards the 5'-hydroxyl 
group, which shortens the coupling time significantly. The resultant phosphite triester 
is not very stable and readily oxidised by iodine/water solution to form a stable 
phosphate triester. The cyanoethyl group in the triester is easily removed by ammonia.
4.3 Automated DNA synthesis:
Automated DNA synthesis involves the following steps:
a) DMT-cleavage: The first nucleoside (usually the 3' end of the DNA sequence) is 
attached to a controlled porous glass or high cross-linked polystyrene support. The 
support can be cleaved by ammonia solution in the final deprotection step. The 5'-OH 
of the nucleoside is protected with the DMT group. During this step dichloroacetic
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acid is used to remove the DMT group and the deprotected 5-hydroxyl group is ready 
for coupling
b) Coupling: During this step the free hydroxyl group reacts with the incoming 
phosphoramidite monomer with activation by tetrazole. The coupling yields are over 
98% and are achieved by using excess phosphoramidite monomer.
c) Oxidation: As the newly formed phosphite triester is unstable, it is converted into a 
stable phosphate triester by oxidation using iodine/water solution.
d) Capping: Since the coupling yield is always below 100%, the un-coupled hydroxyl 
groups are capped to prevent them from reacting with the phosphoramidite during the 
next cycle. In this capping step, acetic anhydride is often used to cap the free 
hydroxyl groups.
Up to this step, a cycle of elongation is completed, and then DNA synthesiser carries 
out successive cycles until the whole sequence of the oligomer is made as shown in 
figure 4.2
DMT— O
Cleavage&
deprotection
Step 1. Deblocking
DMT at 3' of Bj rerr 
sV  5' end is attached to
x  B j  glass
h 3c —c —O— o
(Capping)
B2 O 
DMT— O -J -O —P -
DMT at both 3'&5' are 
removed
Bn O 62 ? !
HO - o -p - o ^ j - o - p - ° - \ r ° Bi
—\ j —O
XttFA 
 
moved 
 porous 
I
OR
IIH3C -C —O -x q —O
Step 4. Oxidati
B'2 B
DMT— O
M onom er
activation
P— N(iPr)2 
OR
+Tetrazole
Step 3 Capping DMT— O - s J - O — P - O ^ j - 0  
OR
free OH group reacts with incoming 
monomer
Step 2. Coupling
Figure 4.2 Schematic representation o f automated DNA synthesis
The automated synthesis is usually carried out by using a standard protocol (details of 
which are usually supplied along with the automated synthesiser).
4.4 Synthesis of base-modified DNA:
(a) Preparation of base-modified nucleosides
Conventionally two major approaches were followed. One approach was to 
synthesise a modified base, and then to join the base with suitably protected 
deoxyribose moiety via chemical coupling or enzymatic method to produce the base 
modified nucleoside. The other approach is direct modification of naturally occurring 
nucleoside.
(b) Conversion of base-modified nucleoside into base modified phosphoramidite
As mentioned earlier the exocyclic amino group of the base-modified nucleoside has 
to be protected for A, G, C with a suitable group. Because thymidine has no 
exocyclic amino group it does not have to be protected. The 5'-OH of the nucleoside 
is selectively protected using dimethoxytrityl chloride (DMTC1) in pyridine. Basic 
conditions are to be maintained as the DMT group is very acid labile as mentioned 
earlier. The 5'-0-DMT protected nucleoside reacts with a phosphitylating agent such 
as 2-cyanoethyl-N,N,N',N-tetraisopropyl phosphoramidite with tetrazole to produce 
the desired monomer. The monomers are stable as solid and can be stored for a long 
time. The dissolved monomer is not stable after a period of two weeks and should not 
be used on automated synthesiser.
(c) Incorporation of the modified phosphoramidite into DNA oligomers by 
synthesiser
In theory the protocols used for standard monomers can be applied for the 
incorporation of base-modified phosphoramidites. But in practice the reactivity of the
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base-modified phosphoramidites could vary due to the nature of the modified base 
and the protecting groups on it, therefore in most cases extra coupling times are 
required to achieve the optimal coupling yields for the base modified monomers. For 
this purpose slight changes to the standard protocol were used for unmodified 
monomers.
4.5 Modification of protocol
A model pentamer containing CGXTA would be synthesised where X being 4- 
thiothymidine. The monomer of Ts is now available commercially (Glen Research, 
USA). This was synthesised using the above mentioned standard protocol. The yield 
was low for ‘X’ i.e., for 4-thiothymidine (less than 60%) when compared to normal 
monomers. Reports [116] suggest that the reactivity of modified base monomer is 
generally low. The lesser reactivity could be generally due to the fact that there is not 
enough time to react and the reagents do not mix properly. So for cycle ‘X’ in the 
standard protocol the coupling time (step-2) was increased. The idea behind this 
could be that the modified monomer would have sufficient reaction time with the 
previous base, thus increasing the coupling yield.
Since the controlled porous glass (CPG) column used for the reactions is very narrow 
the reagents does not mix properly inside. So it requires a manual push and pull step 
with a syringe to allow thorough mixing of monomers to get better yields. So the 
protocol was modified in such a way that it would enable sufficient time for the 
reaction and manual mixing with a syringe. The steps modified are shown in bold in 
the table below:
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MODIFIED PROTOCOL
/ *           -------------------------
/* Function Mode Amount Time(sec) Description
/*
/* — ------------------------------------------------------------ ---—
/Argl /Arg2
$Deblocking
144 /*Index Fract. Coll. */ NA 1 0 "Event out ON"
0 /^Default */ WAIT 0 1.5 "Wait"
141 /*Trityl Mon. On/Off */ NA 1 1 "START data collection"
16/*Dblk */ PULSE 10 0 "Dblk to column"
16/*Dblk */ PULSE 50 49 "Deblock"
38 /^Diverted Wsh A * /PULSE' 40 0 "Hush sys with Wsh A"
141 /*Trityl Mon. On/Off */ NA 0 1 "STOP data collection"
38 /*Diverted Wsh A */ PULSE 40 1 "Hush system with Wsh A
144 /*Index Fract. Coll */ NA 2 0 "Event out OFF"
$Coupling
1 /*Wsh */ PULSE 5 0 "Hush system with Wsh"
2/* Act * /PULSE 12 0 "Hush system with Act"
0 /^Default */ WAIT 0 30 ’’Add the X monomer”
0 /^Default */ WAIT 0 240 ’’Push and Pull”
0 /^Default */ WAIT 0 30 ’’Put Column back”
2 /* Act */ PULSE 4 32 "Couple monomer"
1 /*Wsh */ PULSE 7 56 "Couple monomer"
1 /*Wsh */ PULSE 8 0 "Hush system with Wsh"
$Capping
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12/*Wsh A 
13 /*Caps 
12/*Wsh A 
12/*Wsh A 
$Oxidizing 
15 /*0x 
12/*Wsh A 
$Capping 
13 /*Caps 
12/*Wsh A
*/ PULSE 20
*/ PULSE 8
* /PULSE 6 
*/ PULSE 14
*/ PULSE 15
*/ PULSE
*/ PULSE
*/ PULSE
15
30
0 "Flush system with Wsh A" 
0 "Caps to column"
15 "Cap"
0 "Flush system with Wsh A"
0 "Ox to column"
0 "Flush system with Wsh A"
0 "Caps to column"
0 "End of cycle wash"
There are two advantages of doing this:
a) the modified monomer is given enough time to react with the previous nucleoside 
and
b) because the monomer is expensive only the required amount of monomer needs to 
be diluted to avoid the waste of the monomer since monomers are not stable in 
solution for more than two weeks as discussed earlier.
o
Higher tritylation yields for T monomer (X) were observed when compared to 
normal monomers (C, T and G) as shown in the figure 4.3. Higher tritylation yields 
for (X) modified monomers were also observed using the modified protocol in 
comparison to the suppliers method (tritylation yields when suppliers protocol was 
used not shown).
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Figure 4.3 Tritylation data for pentamer using modified protocol 
A model 12mer was also synthesised to see if the protocol can be used for longer
modified sequences as shown in figure 4.4.
C  T  X  G
M O N O M E R
3 . 5  T  
3
2 . 5  - H  
2
1 . 5  
1
0 . 5
0
iS lS tB
!|raj
□  S e r i e s  1
G C G  X T  C G A A C G  
MONOMERS
Figure 4.4 tritylation data for I2mer sequence. This sequence was synthesised using the same
modified protocol for figure 4.3
High tritylation yields were obtained using the modified protocol even for the longer 
oligomers (in this case 12mer). So the modified protocol enhances the tritylation 
yield for both shorter and longer sequences.
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4.6 HPLC Purification:
Two types of HPLC, reversed phase and anion exchange, are commonly used for the 
separation of short oligomers. When an oligonucleotide is of medium length, reverse 
phase HPLC is not always effective in separating the impurities from the sample. 
Anion exchange HPLC at neutral pH can separate oligomers differing in length by 
only one nucleotide with good resolution. However, to separate an oligomer of 
interest with modified bases from other oligomers of the same length is difficult to 
achieve. Xu et al have described a general procedure for the purification of synthetic 
oligomers of medium length in particular, containing 4-substituted thymine and 6- 
substituted guanine from oligomers of the same length [116]. This general protocol 
was followed for the purification of our synthesised oligomers.
The oligomers (pentamer and 12mer) that were synthesised previously (fig 4.3 & 4.4) 
are subjected to purification. The oligomer was first purified on Nensorb™ 
preparative cartridge. Then it was purified by preparative HPLC. A pure oligomer 
was obtained as shown in figure 4.5 (a).
Ts oligo
259.1
336.1
220 260 340 380300nm
2 C 10 14 18
Minutes
Figure 4 .5: (a) T  incorporated oligo was synthesised using modified protocol (sequence ACTXG)
(b) UV of the oligo
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The UV A,max of the above peak shows presence of the modified base, Ts as it has 
absorption at 330-340nm. The UV was compared with the UV of Ts nucleoside 
(Figure 4.6).
250 300 350nm
Figure 4.6: UV Xmaxo f I s nucleoside 
(Observe the difference in 1st and 2nd crusts)
4.7 Characterisation of the T pentamer:
The incorporation of the I s nucleoside into the pentamer could be confirmed by 
nucleoside composition analysis. The above HPLC-isolated pentamer was subjected 
to enzymatic digestion and five peaks were observed. The new peaks were identified 
by injecting the standard nucleosides. ,
(b) 161s
17.9
220 260 340 380300
(a)
2 6 10 14 18 22
Minutes nm
Figure 4.7: (a) Standard nucleosides were injected together (b) UV Xmax o f standard
nucleosides
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2 6 1 0 ...1 4  1 8  22 220 260 300 340 380Minutes __nm
Figure 4.8: HPLC profile o f nucleoside composition analysis o f the pentamer containing 4- 
thiothymidine. The pentamer (ACTXG) was digested with Nuclease PI and phophodiesterase fo r  30 
minutes. The peak X  has the same retention time as T  standard.
ier
(b)
►7.9
220 340 38024
Minutes
Figure 4.9: The peak X  co-elute with synthesised T  upon co-injection.
This confirms that 4-thiothymidine has been incorporated into the oligomer. This 
oligomer containing 4-thiothymidine can be used for site specific cross-linking.
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4.8 Incorporation of S -BrdU into oligomer
(a) S4-BrdU
oligo
(b)’
2 6 10 14 . 18 22 26 28
Minutes
250 3QP 350
Figure 4.10: A pentamer containing S4-BrdU was synthesised. AGXTC where, X  is S4-BrdU
figure 4.10.
4.9 Activation of modified oligomers
The thiol of the modified oligomers could be activated by a suitable reagent such as 
fluorodinitrobenzene. This would produce S4-2,4 dinitrophenyl containing oligo. 
This group could be replaced by various incoming nucleophiles such as cysteine and 
glutathione. However, we had the difficulty of incorporation dinitrophyenyl group in 
the oligo. This could be due to the fact that Sanger’s reagent is not soluble in water. 
We tried to overcome this problem by synthesising a water soluble reagent that can 
produce a stable and good leaving group when reacted with Ts containing oligo. We 
have chosen diflourodinitrobenzene and substituted one of the fluorine with 
glutathione (was chosen because it was very soluble in water). However our efforts 
did not produce a reagent that can still react with 4-thiothymidine and produce stable 
and good leaving group.
S4-BrdU was incorporated into the oligo and was isolated as a single peak as shown in
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CHAPTER 5 
OVERALL CONCLUSIONS AND FUTURE
PERSPECTIVES
5. Overall conclusions and future perspectives
The overall objective of this project was to make use of the properties of 4- 
thiothymidines to introduce reactive centres into DNA that facilitate cross-linking. At 
the level of individual nucleosides the required chemistry was shown to be feasible 
and some novel reactions with likely nucleophiles were studied.
Thiol group of 4-thiothymidine and 4-thio-5-bromo-deoxyuridine can be site 
specifically activated with a suitable reagent such as l-fluoro-2,4-dinitrobenzene 
(FDNB, Sanger reagent). The activated products S4-2,4-dinitrophenylthiothymidine 
and S4-2,4-dinitrophenylbromodeoxyuridine can be easily separated from the starting 
materials 4-thiothymidine and 4-thio-5-bromodeoxyuridine. The isolated products are 
stable in solution at neutral pH but can undergo hydrolysis at acidic and basic pH. It 
was shown that both S4-2,4-dinitrophenylthiothymidine and S4-2,4- 
dinitrophenylbromodeoxyuridine can be substituted by various thio nucleophiles such 
as mercaptoethanol, ethanethiol, cysteine and glutathione but not by the amino group 
of glycine under similar conditions. These results underline the potential selectivity 
that can be achieved as thiol groups occur much more rarely in proteins than amino 
groups.
The synthesis of oligodeoxynucleotides containing Ts and S4-BrdU was successfully 
achieved and this demonstrated the feasibility of selectively incorporating 
thiothymidines into DNA. Attempts to activate the thio function in oligomers was 
markedly less successful that in isolated nucleosides and it appears that, this is due to 
the insoluble nature of the Sanger’s reagent in water or the repulsion of the fluorine 
by phosphate.
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QActivation of thio! of T containing oligo
The future prospective for this project would be to explore the possibility of cross- 
linking of thiols with the DNA. In order to achieve this, first the thiol group of 
thiopyrimidine containing oligo has to be activated with a suitable reagent like FDNB. 
But selection of a more biological, water soluble, mild reagent would be a better 
choice compared to FDNB. The possibility of selective oxidation of thiol with mild, 
water soluble, oxidative reagent such as magnesium monoperoxyphthalate could be 
explored.
Magnesium bis (monoperoxyphthalate) hexahydrate (monoperoxyphthalic acid 
magnesium salt or MMPP)
2**Mg2
6H20
2
MMPP is a mild oxidizing reagent which is used in many types of oxidation reactions. 
MMPP displays low toxicity when compared to other oxidizing agents such as 
peroxycarboxylic acids. MMPP could oxidize 4-thiothymidine in water to form 
oxidized form of 4-thiothymidine. The product could be sulfoxide or sulfone form of 
4-thiothymidine.
O
.OH
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4-th io thym id ine sulphoxide form  of  4-th iothym idine
su lphone fo r m  of  
4-th io th ym id in e
Once the selective oxidation has been achieved it should be replaceable by simple 
thiol agent such as mercaptoethanol, simple but unique amino acid like cysteine and a 
peptide like glutathione. Once this has been achieved one should look at the most 
interesting aspect and that is protein linking.
Protein -nucleoside cross-link
Protein cross-linking with the nucleoside could be explored first. For this purpose a 
protein containing thiol group like protein disulfide isomerase (PDI) could be chosen. 
PDI is a 57-kDa protein that resides in the endoplasmic reticulum. PDI acts as a 
catalyst in the formation, reduction and isomerisation of disulfide bonds in newly 
synthesised proteins[117]. PDI has five distinct stmctural domains out of which the 
catalytic activity is carried out by the active-site sequence Cys-Gly-His-Cys. So the 
thiol group of this cysteine moiety could be used to cross-link with the activated thiol 
of thiopyrimidines. This would give the opportunity to explore the interaction of 
proteins with nucleoside or DNA (oligo).
CHAPTER 6 
MATERIALS AND METHODS
6 Materials and methods
Chemicals and solvents
Chemicals and solvents were purchased most of the times from either Aldrich or Sigma and were 
used directly without further purification.
Instruments:
TLC: Nucleosides on TLC were identified by using p-anisaldehyde /ethanol/F^SC^ (5:90:5) 
reagent converting the nucleosides into black spots on heating.
HPLC: Waters 2690 with Photodiode array detector (Water 996)
NMR: JNM-LA 300 with FT NMR system
6.1 Synthesis of 4-thiothymidine
6.1.1 Protection of 3' and 5' OH groups of 1
NHNH
O
OH
SiMe3
(1) (2)
2’-deoxythymidine (1, 5.0g, 20,6mmol) was dissolved in dry THF (150ml). 
Triethylamine (63.4ml, 0.454mmol) was added followed by addition of 
trimethylchlorosilane (6.34ml, 81.2mmol). The reaction mixture was stirred in an ice 
bath, with continuous stirring for an additional 2.5 hours after all the materials were
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added. TLC showed no starting material. The reaction mixture was diluted with 50% 
ethyl acetate , in hexane (250ml), washed with water (2 x 100ml) and saturated 
aqueous sodium chloride (80ml). The combined organic phase was dried (Na2S0 4 ) 
and evaporated to give the protected thymidine (2, 3', 5'-bis-trimethylsilyl-2’- 
deoxythymidine). Yield 65%.
6.1.2 Synthesis of 3
1,2,4-1# triazole (6 .8 g, 98.4mmol) was suspended in 80ml of anhydrous acetonitrile 
at 0°C. 2.1 ml of POCI3, then 16ml of triethylamine was added slowly. After an hour 
2 (2.6g, 6.7 mmol) in 30ml of acetonitrile was added over 30min. Then the solution 
was stirred for 16 hours at room temperature and reaction was monitored by TLC. 
The reaction mixture was filtered diluted with ethyl acetate (160ml) and washed with 
saturated aqueous sodium chloride. The organic layer was dried over anhydrous 
sodium sulphate and the solvent evaporated under reduced pressure to give 3. Yield
? 01
SiMe3
(2)
Me3Si
(3)
60%.
v
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6.1.3 Synthesis of 4
NH
(3) <4)
To a solution of 3 (2.62g, 6.0mmol) in 120ml of acetonitrile was added 6ml (6.39g, 
83.9mmol) of thiol acetic acid in an ice water bath. The reaction was stirred overnight 
and monitored by TLC until the starting material converted to a new spot. The 
solution was diluted with dichloromethane (250ml), washed with saturated NaHCC>3 
(2X250ml), then with saturated aqueous sodium chloride (250ml). The organic layer 
was dried over sodium sulphate and evaporated under reduced pressure to give crude 
product. Pure compound 4 was obtained by silica gel column chromatography. Yield 
58%.
XH NMR [DMSO-de] 9.18 (1H, s, 3-H of triazolo), 8.48 (1H, s, 6H)), 8.24 (lH,s, 5-H 
of triazolo), 6.01(1H, t, l'H), 5.19 (1H, d, 3'-OH), 5.10 (1H, t, 5'-OH), 4.13(1H, m, 3'- 
H), 3.78 (1H, m, 4 '-H), 3.59 (2H, m, 5 '-H), 2.07-2.2 (2H, m, 2'H ), 2.18 (3H, s 5- 
CH3).
13C NMR [DMSO-d6] 16.2 (5-CH3), 40.9 (0 2 '), 60.4(05'), 69.2(03'), 86.9(C-1'), 
88.1(04'), 104.4(C-5), 145.2(06), 147.9 (0 4 ), 153.1(triazole C), 153.4(triazole C), 
157.7(02).
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6.1.4 Synthesis of 5
The trimethylsilyl groups are unstable in the presence of acid and 4-thiothymidine (5) 
is produced by the treatment of 4 with acetic acid in methanol.
NH
01
SiMe3
NH
HO,
OH
(4) (5)
Addition o f acetic acid deprotects 3' & 5' hydroxyl groups
6.2 Synthesis of 6.
NO.
NO
NHNH
+ HXO
HO, HO,
OH OH
5 6
(a) Reaction with C1DNB:
4-thiothymidine (14mg, 5.4pmoles) was dissolved in 1ml of acetonitrile. 12mg 
(5.9[xmoles) of 1-Chloro 2,4-dinitro benzene was dissolved in 1ml of acetonitrile (or
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DMF). 200pl of phosphate buffer (pH 9.5 1M) was added and the reagents were 
mixed thoroughly using a whirl mixer.
(b) Reaction with FDNB:
4-thiothymidine (14mg, 5.4pmoles) was dissolved in 1ml of acetonitrile. 8 mg 
(4.3[xmoles) of Flouro 2,4-dinitro benzene was dissolved in 1ml of acetonitrile (or 
DMF). 200pl of phosphate buffer (pH9.5 1M) was added and the reagents were 
mixed thoroughly using a whirl mixer.
(c) HPLC monitoring of the reactions
2 0 0 pl of each of the above reaction mixtures were diluted with 1 ml of water before 
injecting on HPLC. The reaction was monitored by HPLC on a PHENOMENEX, 
(250x4.6 mm 4\i synergy analytical column [Conditions: flow rate 0.3 mL/min. 
Reservoir A: H2O; Reservoir B: CH3CN; Reservoir C of 0.1 M phosphate buffer (pH 
6.52) is kept constant at 5%; the percentage of CH3CN was increased from 5% to 75% 
during the first 2 0  min]
When the starting material was completely disappeared, the product 6  ( t sdnp) at 
retention time 13.4 minutes was isolated by preparative HPLC.
(d) Isolation of the peak
Reversed phase preparative HPLC (Phenomenex Synergi Max 250 x 10mm column) 
was used for isolation 6 . The peak at retention time 13.4 minutes with ^max of 314.7 
nm was collected using a Waters™ 616 pump, 996 photodiode array detector and 
717Plus auto-sampler. The following program was used:
Time Flow %B %C %D
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0 4.00 90.0 5.0 5.0
20.00 4.00 20.0 75.0 5.0
30.00 4.00 5.0 90.0 5.0
30.01 4.00 90.0 5.0 5.0
Mobile phase B was water, mobile phase C was acetonitrile, mobile phase D was 
0.1M KH2PO4 buffer (pH 6.6). The purified and collected 6 was re-analysed by 
analytic HPLC and showed a single peak.
Spectral data for TSDNP
The isolated pure peak was subjected to mass spectroscopic analysis and the mass 
fragments were obtained under different electrospray conditions. The observed 
fragments were 424 M+, 423 (M+-H)+ and 425 (M+H)+.
UV 314.7 nm
6.3 Attempted synthesis of S4-mononitrophenyl derivatives
5 (1.2mg, 4 mmoles) was dissolved in lOjil of water. l-Fluoro-2-nitrobenzene (1.2mg, 
8 nmoles) or l-fluoro-4-nitrobenzene (1.4mg, 10 nmoles) was dissolved in 20nl of 
dimethyl formamide (DMF). Phosphate buffer (20nl, pH 9.5) was added to the 
combined solutions and the reactions were monitored by HPLC by diluting lp l of 
reaction mixture to 10 with water and injecting 5nl after lhour and 48hours
6.4 Stability of 6 in aqueous solutions:
A solution of 6 in 0.1 M phosphate buffer, pH 6.52 was mixed with an equal-volume 
of 1.0 M phosphate buffers of specific pH (4, 5, 6,7,8 9 and 10), then the solution was 
left in RT for 24 hours or 9 days at which time the solution was analysed by HPLC.
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Conditions for monitoring the reactions
Waters 2690 Alliance HPLC, (996 photodiode array detector fitted) was used. 
Atlantis dC18 5pm 2.1X150mm column with mobile phase B as water, mobile phase 
C as acetonitrile, mobile phase D as 0.01M KH2PO4 buffer (pH 6.8) and the program 
used was,
Time Flow %B %C %D
0.0 0.30 90 5 5
20.0 0.30 20 75 5
20.1 0.30 90 5 5
The programme was run for 20 minutes and the time left for equilibration was 15 
minutes. The sample temperature was maintained at 4°C throughout the experiment. 
The column temperature was maintained at 30°C.
The HPLC analysis showed three peaks with retention times 7.1 minutes (the 
hydrolysed product: thymidine), 10.2 minutes (the leaving group of
dinitrophenylthiol) and 14.7 minutes (the starting material: S4-2,4-
dinitrophenylthiothymidine) respectively. Each sample was analysed for three times 
and the values were averaged.
The percentage of the degradation of 6 was calculated and the values averaged. The 
averaged values for the hydrolysis of t sdnp and the averaged values for the thymidine 
formed were taken into consideration for plotting the graph.
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6.5 Reaction of 6 with various nucleophiles
6.5.1 Reaction with mercaptoethanol
To a solution of of 6 (150pL [1 OD] in 0.01M phosphate buffer [pH 6.52]) was added 
lOpL of mercaptoethanol from a stock solution (lOpL diluted with 1ml of water). 
Atlantis™ Qg 5p (2.1x150mm) column and Waters™ 2690 with photo diode array 
detector were used.
Conditions: flow rate 0.3 mL/min. Reservoir A: H2O; Reservoir B: CH3CN; Reservoir 
C of 0.1 M phosphate buffer (pH 6.52) is kept constant at 5%; the percentage of 
CH3CN was increased from 5% to 75% during the first 20 min, monitored at 260 nm.
The same HPLC conditions were used for co-injections with the synthesised standard 
and determining the characteristics of the compound 2 -hydroxyethylthiothymidine.
6.5.2 Reaction with cysteine
To a solution of 6  (150pL (1 OD) in 0.01M phosphate buffer (pH 6.52)) was added 
2mg (0.0164mmol) of cysteine. Atlantis™ Cig 5p (2.1x150mm) column was fitted to 
Waters™ 2690 with photo diode array detector.
The conditions used were flow rate 0.3 mL/min. Reservoir A: H2O; Reservoir B: 
CH3CN; Reservoir C of 0.1 M phosphate buffer (pH 6.52) is kept constant at 5%; the 
percentage of CH3CN was increased from 5% to 75% for 20 min, monitored at 260 
nm. The sample temperature was maintained at 20° C for N4-cysteinylthymidine (S4- 
cysteinylthymidine was not observed in these conditions).
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The above mentioned conditions were maintained apart from the sample temperature 
(which was maintained at 5°C) and all the solutions were pre-cooled before mixing. 
At this stage S4-cysteinylthymidine was observed for shorter period of time.
6.5.3 Reaction of 6 with cysteine and glycine.
To a solution of 150 pL of 6  [containing 1 OD of TSDNP in 0.01 M phosphate buffer 
(pH 6.52)] was added 16 mg (0.13 mmol) of cysteine or 56 mg (0.74 mmol) of 
glycine. The reactions were monitored by HPLC immediately and after 24 hours.
HPLC conditions: Atlantis™ Cig 5 micron (4.6 x 250mm) column; flow rate 0.3 
mL/min; Reservoir A: H2O; Reservoir B: CH3CN; Reservoir C of 0.01 M phosphate 
buffer (pH 6.52) is kept constant at 5%; the percentage of CH3CN was increased from 
5% to 90% during the first 20 min, monitored at 260 nm].
6.5.4 Reaction with glutathione
To a solution of 150pL of 6  (1 OD) of TSDNP in 0.01M phosphate buffer (pH 6.52) 
was added 1.5mg (0.0048mmol) of glutathione. The sample temperature was 
maintained at 5° C. The gradient was mn for 20 minutes. Phenomenex™, 2p Synergy 
analytical column used. The gradient was run as follows.
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Time flow %A %B %c %D
1 - 0.30 0 . 0 90.0 5.0 5.0
2 2 0 . 0 0.30 0 . 0 2 0 . 0 75 5.0
3 2 1 . 0 0.30 0 . 0 90.0 5.0 5.0
4 28.0 0.30 0 . 0 90.0 5.0 5.0
5 28.1 0.30 0 . 0 90.0 5.0 5.0
6.6 Synthesis of Standards
6.6.1 Synthesis of 4-triazolothymidine (11),
NH
HO
OH
(1) (3)
This synthesis was based on a previously reported protocol[99] . Thymidine (1.22g,
5.04 mmol) was suspended in dry THF (50 mL) in an ice bath. Triethylamine (11 mL, 
78.26 mmol) and chlorotrimethylsilane (3.5 mL, 27.38 mmol) were added to the 
suspension drop by drop. The colour of the solution remains white. After 5 hours TLC 
showed one major spot (95%) and two minor spots (in 10% CH3OH/CHCI3). Then, 
the reaction mixture was cooled again (ice water bath), under continued stirring 1,2,4- 
lH-triazole (4g, 57.92 mmol) was added and phosphorous oxychloride (1 mL, 10.69 
mmol) added dropwise. The reaction was left stirring overnight. The solution turned
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to yellow, and was poured into saturated aqueous sodium hydrogen carbonate (300 
mL) and resultant mixture was extracted with dichloromethane (2 x 50 mL).
HO.
OHO
Me3Si
(3) (11) .
The combined organic extracts were dried (MgSCL) and evaporated under reduced 
pressure. Acetic acid-methanol (1:4 v/v, 15 mL) was added to the residue, and the 
resulting solution was allowed to stand at RT overnight. Diethyl ether (30 mL) was 
added drop by drop, with stirring; to this solution over a period of 30 min. Colourless 
crystals of 11 (660 mg, yield 45%) were collected by filtration.
M.P. 175°C.
*H NMR [DMSO-d6] 9.18 (1H, s, 3-H of triazolo), 8.48 (1H, s, 6 H)), 8.24 (lH,s, 5-H
of triazolo), 6.01(1H, t, 1 'H), 5.19 (1H, d, 3'-OH), 5.10 (1H, t, 5'-OH), 4.13QH, m, 3'-
H), 3.78 (1H, m, 4 '-H), 3.59 (2H, m, 5 '-H), 2.07-2.2 (2H, m, 2'H ), 2.18 (3H, s 5-
%
CH3).
13C NMR [DMSO-d6] 16.2 (5-CH3), 40.9 (C-2'), 60.4(C-5'), 69.2(C-3'), 86.9(0-10, 
88.1(C-4'), 104.4(C-5), 145.2(C-6), 147.9 (C-4), 153.1(triazole C), 153.4(triazole C),
157.7 (C-2).
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The compound was subjected to mass spectroscopic analysis and the mass fragments 
were obtained under electrospray conditions. The observed fragments were:
M+ 293, M+-H 292 and M+H 294.
6.6.2 Synthesis of 2-hydroxyethylthiothymidine (8):
OH
dRdR
(11) (8)
11 (lOOmg, 0.35mmoles) was dissolved in methanol (15ml), to which 
mercaptoethanol (50pil, 0.70mmoles) and triethylamine (50pl, 0.35mmoles) were 
added. The reaction was monitored by thin layer chromatography (TLC) using 50% 
methanol in chloroform. The starting material (Rf=0.34) was immediately and 
completely converted to a new spot with low Rf =0.20. The solvent was evaporated 
under reduced pressure. The residue was re-dissolved in methanol and put in a 
container with diethyl ether. White crystals of 8  were obtained in a yield of 80%. The 
product was confirmed to be p-hydroxyethylthiothymidine by spectral data:
’H NMR Data (in DMSO-d6): 1.95 (3H, s, 5-methyl), 2.01-2.28 (2H, m, 2' and 2"-H),
3.21 (2H, t, a-methylene), 3.60 (4H, m, 5'-H, and p-methylene), 3.83 (1H, dd, 4'-H),
4.21 (1H, m, 3'-H), 5.01 (1H, t, 5'-OH), 5.24 (1H, d, 3'-OH), 6.06 (1H, t, l'-H),
7.9817 (1 H, s, 6 -H).
13C NMR (in DMSO-d6) 13.67 (5-CH3), 59.35 (C-5’), 60.81 (P-C of OH), 69.77 (C- 
3’), 85.17 (CM*), 87.73 (C-4’), 110.44 (C-5), 138.60 (C-2), 152.43 (C-6 ), 176.2 (C-2)
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UV Xrnax- 308.8; MS m/z: 302.88 (M) 186.9 [(M+ H) - sugar) and the mass fragments 
were obtained under electro spray conditions. The observed fragments were M+ 302, 
M+-H 301 and M+H 303.
6.6.3 Synthesis of 4-cysteinyIthymidine (20).
H OH
H2C— C------- C
SH HN O
dR dR
(11) (20)
11 (100 mg, 0.35 mmol) in 15 ml of water was treated with cysteine (lOOmg,
0.82mmoles) and triethylamine (50 pi, 0.35mmoles). The reaction was monitored by 
TLC (40% methanol in chloroform). The starting material (Rf=0.58) was completely 
converted to a new spot with low Rf=0.20 immediately. The solvent (water) was 
removed by freeze-drying. The residue was purified with a silica gel column 
chromatography (40% methanol in chloroform). The product was collected and re­
crystallised from methanol and diethyl ether. 90mg of 20 was obtained (yield 75%).
JH NMR Data (in DMSO-d6): 1.90 (3H, s, 5-methyl), 1.95-2.10 (2H, m, 2'-H & 2 "-
H), 3.15 (2H, m, P-CH2), 3.5341 (2H, m, 5'-H), 3.7410 (1H, m, 4'-H), 4.2536 (1H, m,
3'-H) 4.47 (1H, m, a-CH), 5.02 (1H, br, 5’-OH), 5.19 (1H, br, 3’-H), 6.1546 (1H, t, I'­
ll), 6.8252 (1H, s, N-H), 7.6350 (1H, s, 6 '-H).
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13C NMR Data (in DMSO-d6): 12.77 (5-CH3) 25.82 (P-C of linked cysteine), 45.41 
(C-2’), 56.07 (a-C of linked cysteine), 61.72 (C-5’), 65.00 (No proton-attached), 70.4 
(C-3’),84.63 (C-l’), 87.09 (C-4’), 101.49 (C-5), 137.80 (C-6 ); 154.95 (C-2), 161.80 
(C-4). UV XmaX: 278 nm; HRMS (electrospray): m/z 346.1071 ([M++l])
6.6.4 Synthesis of 4-glutathionyl-p-thiothymidine
lutathione
dRdR
(11) (24)
9 (100 mg, 0.35 mmol) was dissolved in 25 ml of water, to which glutathione (150 
mg, 0.52 mmol) and triethylamine (50 pi, 0.36 mmol) were added at room 
temperature. The reaction was monitored by TLC (50% methanol in chloroform). 
The starting material was converted to a new spot immediately. The solvent (water) 
was removed by freeze drying. The white precipitator was obtained in quantitative 
yield. HPLC analysis shows a major peak (purity over 95%). Structural 
characterisation:
UV ^maX: 309nm; HRMS (electrospray): m/z 532.1705 ([M++l]).
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6.7 Data for DTT experiments:
DTT (6 mg, 39pmoles of stock prepared and 10 pi, from the stock 0.39 pmoles) was 
added to peak 4. Peak 3(Tcys) was purified on HPLC which forms peak 4 on standing 
for overnight. This newly formed peak has the same UV absorption at 278 like Tcys. 
HPLC setup:
Waters 2690 Alliance HPLC, (996 photodiode array detector fitted) was used to 
monitor the reaction of TSDNP with Cysteine. Atlantis dQg 5pm 2.1X150mm 
column with mobile phase A as methanol, mobile phase B as water, mobile phase C 
as acetonitrile, mobile phase D as 0.01M KH2PO4 buffer (pH 6 .8 ) and the program 
used was,
Time Flow %B %C %D
0 . 0 0 0.30 95 0 5
25.00 0.30 60 35 5
26.00 0.30 : 25 70 5
30.00 0.30 25 70 5
31.01 0.30 95 0 5
The program was run for 25 minutes and the time left for re-equilibration was for 
25minutes. The sample temperature was kept at 4°C throughout the experiment. The 
column temperature was maintained at 30°C.
6.8 *H and 13C NMR data of modified thymidine nucleosides:
!H NMR of thymidine analogues
l ’-H 2’-H c h 3 3’-H 4’-H 5’-H
O
1
CO 5’-OH 6 -H NH P-methylene
a 6.06 2 . 0 1 1.95 4.21 3.83 3.60 5.24 5.01 7.98 n/a 3.60
b 6.15 ' 1.95 1.90 4.25 3.74 3.53 5.19 5.02 7.63 6.82
c 6 . 0 1 2.07 2.18 4.13 3.78 3.59 5.19 5.10 8.24 n/a
d 6.06 2.09 N/A 4.22 3.76 3.53 5.24 5.16 8.38 11.77
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13C NMR of thymidine analogues
c h 3 l ’-C 2’-C 3’-C 4’-C 5’-C 2-C 4-C 5-C 6 -C
a 13.67 85.17 40.6 69.77 87.73 59.35 138.60 176.2 110.44 152.43
b 12.77 84.63 45.41 70.4 87.09 61.72 154.95 161.80 101.49 137.80
c 16.2 86.9 40.9 69.2 8 8 . 1 60.4 153.1 157.7 104.4 145.2
d N/A 84.84 40.05 69.96 87.56 60.81 149.77 159.20 95.69 140.31
а)P-hydroxyethylthiothymidine:
XH NMR Data (in DMSO-d6): 1.95 (3H, s, 5-methyl), 2.01-2.28 (2H, m, 2’ and 2"-H),
3.21 (2H, t, a-methylene), 3.60 (4H, m, 5'-H, and P-methylene), 3.83 (1H, dd, 4'-H),
4.21 (1H, m, 3'-H), 5.01 (1H, t, 5'-OH), 5.24 (1H, d, 3'-OH), 6.06 (1H, t, l'-H),
7.9817 (1H, s, 6 -H).
13C NMR (in DMSO-d6) 13.67 (5-CH3), 85.17 (C-l’), 69.77 (C-3’), 87.73 (C-4’), 
59.35 (C-5’), 60.81 (P-C of OH), 138.60 (C-2), 176.2 (C-4), 11-0.44 (C-5), 152.43 (C-
б )
b)4-CysteinyI thymidine:
XH NMR (in DMSO-d6): 1.90 (3H, s, 5-methyl), 1.95-2.10 (2H, m, 2’-H & 2"-H), 
3.15 (2H, m, p-CH2), 3.5341 (2H, m, 5’-H), 3.7410 (1H, m, 4’-H), 4.2536 (1H, m, 3’- 
H), 4.47 (1H, m, a-CH), 5.02 (1H, br, 5’-OH), 5.19 (1H, br, 3’-OH), 6.1546 (1H, t, 1’- 
H), 6.8252 (1H, s, N-H), 7.6350 (1H, s, 6 ’-H).
13C NMR (in DMSO-dg): 12.77 (5-CH3) 25.82 (P-C of linked cysteine), 45.41 (C-2 ’),
56.07 (a-C of linked cysteine), 61.72 (C-5’), 65.00 (No proton-attached??? C02?)
70.4 (C-3’), 84.63 (C -l’), 87.09 (C-4’), 101.49 (C-5), 137.80 (C-6 ); 154.95 (C-2), 
161.80 (C-4)
c)l,2,4 triazolothymidine:
XH NMR [DMSO-d6] 9.18 (1H, s, 3-H of triazolo), 8.48 (lH,s, 5-H of triazolo), 8.24 
(lH,s, 6 H), 6  01(1H, t, l ’H), 5.10 (1H, t, 5’-OH), 5.19 (1H, d, 3’-OH), 4.13(1H, m,- 
3’-H), 3.78(1H, m, 4’-H), 3.59(2H, m, 5’-H), 2.07 (2H, m, 2’H ), 2.18 (3H, s 5-CH3). 
13C NMR [DMSO-d6] 16.2 (CH3), 40.9(C2’), 60.4(C5’), 69.2(C3’), 86.9(C1’), 
88.1(C4’), 104.4(C5), 145.2(C6?), 147.9(triazole C), 153.1(C2?), 153.4(triazole C),
157.7 (C4?).
d)5-Bromo-2,-deoxyuridine:
XH NMR [DMSO-dg]: 2.09-2.14 (2H, m, 2’-H & 2”-H), 3.53-3.64 (2H, m, 5’H), 
3.76-3.79 (1H, m, 4’H), 4.22-4.23 (1H, m, 3’H), 5.16 (1H, br, 5’OH), 5.24 (1H, br, 
3’OH), 6.06-6.11 (1H, t, l ’H), 8.38 (1H, s, 6 H), 11.77 (1H, br, N-H)
13C NMR [DMSO-d6] 40.05(C2’), 60.81(C5’), 69.96 (C3’), 84.84 (C l’), 87.56 (C4’), 
95.69 (C5), 140.31 (C6 ), 149.77 (C2), 159.20 (C4).
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6.9 HPLC conditions for S4-BrdU reactions:
Column details: XTerra® MS Qg 3.5pm, 2.1X150mm column.
Time Flow %'A %B %D
0 . 2 0 93.0 2 . 0 5.0
1 0 . 0 0 0 . 2 0 75.0 2 0 . 0 5.0
2 0 . 0 0 0 . 2 0 65.0 30.0 5.0
2 0 . 0 1 0 . 2 0 65.0 30.0 5.0
30.00 0 . 2 0 15.0 80.0 5.0
35.00 0 . 2 0 15.0 80.0 5.0
35.01 0 . 2 0 93.0 2 . 0 5.0
%A Water 
%B Acetonitrile
%C buffer (0.01M KH2P 0 4 buffer pH6.55)
6.10 Chemicals and enzymes for DNA synthesis and oligomer analysis:
The CPG-linked monomers and the chemicals used on the synthesiser were obtained 
from Cruachem (Glasgow, Scotland) and the phosphoramidite protected monomers 
(including 4-thiothymidine) from Glen Research Corporation. Activator solution, 
Cap-A, B solutions, Oxidising solution, and acetonitrile solution was obtained from 
Cruachem (Glasgow, Scotland). The phosphatase, alkaline from bovine intestinal 
mucosa and phosphodiesterase II from bovine spleen were obtained from Sigma. 
Acetonitrile (HPLC grade) was dried with molecular sieves for at least 48 hours. All 
the chemicals used for chromatographic separation and Nensorb prep were HPLC 
grade including water.
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(a) Monomers:
The monomers are generally protected as follows:
• The 5’-hydroxyl positions are protected with DMT groups
• Phosphorous is protected with diisopropyl amine groups and a p-cyanoethyl 
group.
• The exocyclic amines of adenosine, guanosine and cytidine are protected with a 
new, stable base protecting group such as tertiary butylphenoxyacetyl (tBPA).
• Thymidine does not need to be protected.
• Monomer 4-thiothymidine (Ts) was obtained from Glen Research for the 
synthesis of modified oligomers. The sulphur at position 4 of thymidine is 
protected with cyanoethyl group and removable under basic condition.
(b) Synthesis of oligomers
5'ATTGC3' sequence was synthesised using DNA synthesiser (Expedite™ 8908). The 
final tritylation yields were 80%. 1ml of ammonia solution was added and left 
overnight to cleave the oligonucleotide from the support. DMT of the last nucleotide 
(in this case adenine) was left on for Nensorb™ prep cartridge purification. The 
oligonucleotide was purified as per the manufacturer's instruction and nine fractions 
of lml were collected into 1.5ml micro centrifuge tubes. All the samples were 
checked for UV absorbance. Maximum yields were obtained in fraction four and 
five. These fractions were diluted to 20times (50j l l 1 made up to lml with water) and 
the absorbance was taken. Fractions 4 and 5 were vacuum dried and labelled as TSR- 
N1 (4 & 5 respectively) for future use.
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(c) Synthesis of oligomers with modified base (T )
5'ATXGC3' sequence was synthesised (the tritylation yields were about 60%) and 
purified as exactly mentioned above except for the deprotection step which was 
carried out with 50mM NaSH in concentrated NH4OH for 24hrs at room temperature. 
Fractions 4, 5& 6  of the collections gave the maximum yield. This was diluted for 20 
times (50|il of sample + 950pl of water) and UV absorbance was taken. The samples 
were dried under vacuum and labelled as TSR-MOD 1 (4, 5& 6  respectively) for 
further studies. Similarly TSR-12mer (5'CGC AAG CTX GCG 3') was synthesised 
and stored. 'X' in this sequence denotes 4-thiothymidine. Absorbance at 330nm was 
observed during UV measurement for the modified oligomers (4-thiothymidine has 
maximum absorption at 330nm).
6.11 Purification of oligomers
Oligodeoxynucleotides (TSR N l) 5ATTGC3', (TSR MODI) 5ATXGC3' and 
(TSR12mer) 5’CGC AAG CTX GCG3' were synthesised by Expedite™ 8908 DNA 
synthesiser. The purification of oligodeoxynucleotides was carried out in two stages: 
first, crude synthetic oligomers with DMT on the 5'-OH of the terminal nucleotide 
were isolated and partially purified with Nensorb™ prep cartridges (Du Pont, U.S.A). 
During this stage, the failure sequences without DMT on the 5'-terminus was 
removed, .and the sequences ATTGC, ATXGC and CGC AAG CTX GCG were then 
detritylated and eluted from the cartridge. These are only partially purified oligomers. 
HPLC was employed to obtain the oligomers of highest purity.
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(a) Purification of oligomer using Nensorb™ cartridge:
Nensorb™ prep cartridges can be used for the simultaneous purification and 
detritylation of milligram quantities of oligonucleotides obtained from automated 
synthesisers. Trityl-on oligonucleotides are applied to the Nensorb prep™ cartridge 
in 0.1M triethylammonium acetate (TEAA), pH 7.0 or concentrated ammonium 
hydroxide. Salts, failure sequences, and synthetic by-products are washed away while 
the trityl on oligonucleotide remains bound to the cartridge. The trityl group is then 
hydrolysed from the 5'-end of the oligonucleotide with a 0.5% trifluoroacetic acid 
wash, leaving the trityl wash oligonucleotide bound to the cartridge. Subsequent 
recovery of the purified, trityl-off oligonucleotide is accomplished with a 35% 
methanol wash.
(b) Procedure for oligonucleotide purification and detritylation:
For maximum yield from Nensorb prep:
• The synthetic oligonucleotide must contain a 5' trityl group
• Drying of resin bed should be avoided during wash steps
• Maximum amount of oligonucleotide which can be purified and detritylated is 50
O.D units (lmg)
(c) Sample Preparation
1. After automated synthesis and deblocking with ammonium hydroxide the 
oligonucleotide must be left in the DMT (trityl-on) state.
2. The oligonucleotide is loaded directly in concentrated NH4OH if lower recoveries 
can be tolerated.
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(d) Cartridge Preparation
1. Clamp the Nensorb Prep cartridge to a secure support.
2. Attach one tubing adaptor to the Nensorb prep cartridge and the other to a plastic
syringe.
3. Activate with 10ml of methanol. Flow rate not to exceed lOml/min while pulling
solvent through the column.
4. Pre equilibrate the cartridge with 5ml 0.1M TEAA, pH 7.0
(e) Oligonucleotide purification
1. Pipette the sample, which has been dissolved in 4ml of 0.1 M TEAA, pH 7.0, on 
the top of resin bed. Pull the sample through resin bed until meniscus reaches top 
of the bed.
2. Wash the cartridge with 10ml of acetonitrile/0.1 M TEAA pH 7.0 (1:9). Failure 
sequences, salts, and synthetic by-products are washed away in this step while the 
trityl on oligonucleotide remains bound to the cartridge.
(f) Detritylation and recovery of the purified trityl off oligonucleotide
1. Wash cartridge with 25ml of 0.5% TFA. The trityl group is hydrolysed in this 
step with the trityl-off oligonucleotide remaining bound to the resin.
2. Wash cartridge with 10ml of 0.1M TEAA, pH 7.0 to remove acid.
3. Replace 20ml syringe with a 3ml plastic syringe. Add 10ml of 35% 
methanol/water to the cartridge. Pull lml fraction to a 1.5ml micro centrifuge 
tube. Collect 10 fractions.
143
4. Check the 0.D of each fraction to locate the purified trityl off oligonucleotide. It 
is usually found in fractions 3 to 6  with majority at 4 or 5
5. Dry the desired fractions by lyophilization or vacuum centrifugation. The 
oligonucleotide should be stored dry and is reconstituted immediately before use.
6.12 HPLC Conditions for purification
Both analytical (Phenomenex Luna 5p, C l 8  (2), 25cm/4.6mm ID) and semi 
preparative (Phenomenex synergi 25cm/10mm ID) columns were used to purify 
modified and normal pentamers. Analytical column was fitted to Varian 9065 
instrument and semi preparative to Varian 5000. For analytical purpose gradients 
were formed from 0.01M aqueous KH2PO4 (pH 6.5) (buffer A with 2% CH3CN) and
0.01M aqueous KH2PO4 (pH6.5) (buffer B with 40% CH3CN) at a flow rate of 
lml/min. For preparative procedure gradients were formed from 0.1M TEAA (pH 
6 .8 ) (buffer A with 2% CH3CN) and 0.1M TEAA (pH 6 .8 ) (buffer B with 40% 
CH3CN). Oligomers were further purified and vacuum dried.
6.13 Nucleoside composition analysis
The purity of the oligomers can be assessed by analysis of nucleoside digest. 
Generally, 0.5 A260 unit of oligomer was dissolved in 160pL of H2O and 20|iL of 
600mM Tris-HCl, 60mM MgCL, and pH 8.5. Nuclease PI (10|iL, lOjig of protein) 
was added and the mixture incubated (37°C, 30 min), and then alkaline phophatase 
(10pL, 5jig of protein) was added and incubation continued for 30min. The 
deoxyribonucleosides were separated by HPLC. The chromatography was monitored 
at 260nm for the detection of dC, dG, T and dA and at 335nm for 4-thiothymidine.
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There was very good absorbance at 335nm, which confirms the presence of 4-thio 
thymidine in the oligomer ATXGC.
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APPENDIX
BIOL 374-Thiothymidine as a potent pro-drug and its use for DNA crosslinking
rasa Rao Tummala, David E Shuker, and Yao Zhong Xu. Department of Chemistry, Open University, Venables Building, Walton Hall
Campus, Milton Keynes, MK7 6AA, United Kingdom
listinctive photochemical properties of DNA thiobases have not been extensively evaluated for their therapeutic potential (Favre et al; 
’hotochem Photobiol B 1998,42:109-124). Recently our group (Massey et al; Current Biology, 2001,11:1142-1146) reported the 
Dration of thiopyrimidine nucleoside, 4-thiothymidine as a pro-drug into DNA of cancerous cells and the use of nonlethal UVA doses to 
lem. This thiobase/UVA treatment may offer a new therapeutic approach for non-malignant conditions like psoriasis or for superficial 
mors that are accessible to phototherapy. This type of therapy has an advantage over the conventional therapies as it targets the 
bus cells selectively. More recently, we also reported the chemical synthesis and incorporation of (4-thiothymidine analogue) pro-drug
5-bromo-2'-debxyuridine (Xu et al; Bioorganic and medicinal chemistry letters, 2004,14:995-997). While investigating the mechanism 
toxicity of these pro-drugs we have found that the thio group of 4-thiothymidine can be selectively activated to a stable but readily 
aced functional group. This can be readily converted to desired targets, thus offering a novel synthetic route to 4-modified thymidine 
igues and a valuable tool for chemical manipulation including site specific crosslinkings with other macromolecules, DNA or proteins.
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